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University of Pittsburgh, 2008
 
Dendritic cells (DC) are a heterogenous population of antigen presenting cells important in both 
innate and adaptive immune responses.  The two major subsets of DC, CD11c+ myeloid DC 
(mDC) and CD123+ plasmacytoid DC (pDC), are depleted in the blood of human-
immunodeficiency virus (HIV) – 1 infected individuals.  It has been proposed that DC loss may 
be due to lymph node recruitment, direct viral infection, bone marrow suppression or death, 
although this has not been directly addressed.  Using the highly relevant, rhesus macaque/simian 
immunodeficiency virus (SIV) model of HIV infection, we investigated DC dynamics during 
acute pathogenic SIV infection and simian AIDS.  We hypothesized that SIV infection causes 
a dysregulation of DC trafficking and death not solely dependent upon direct viral 
infection.  The specific aims of this project are to: 1) determine the phenotypic heterogeneity of 
DC in blood from healthy macaques and develop a rapid assay for frequent longitudinal 
quantitation of absolute DC numbers; 2) determine whether mDC and pDC are recruited to 
lymphoid tissues in simian AIDS; 3) determine the dynamics and possible mechanisms of pDC 
loss and redistribution to lymphoid tissue during acute SIV infection.   We found that rhesus 
macaque DC were more phenotypically homogeneous than their human counterparts and could 
be accurately quantified in small volumes of blood.  In monkeys with simian AIDS, DC were 
depleted in both blood and secondary lymphoid tissues associated with increased spontaneous 
apoptosis.  However, the remaining DC were phenotypically normal.   During acute SIV 
infection, pDC responded to infection in a biphasic manner, with rapid mobilization into blood 
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followed by depletion in both blood and lymphoid tissue.  However, pDC production from bone 
marrow was normal and BrdU-labeling indicated increased pDC mobilization and recruitment to 
lymphoid tissues despite net loss of pDC.  In lymph nodes, pDC were directly infected with 
virus, activated, and undergoing increased levels of apoptosis but retained functional TLR7 
signaling.  The findings in this study are significant to public health because defining the 
mechanisms leading to DC loss will offer new opportunities for therapeutic interventions to 
augment immune responses in HIV-infected individuals.   
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1.0  INTRODUCTION 
1.1 GLOBAL HIV EPIDEMIC 
Human immunodeficiency virus type 1 (HIV-1), the causative agent of acquired immune 
deficiency syndrome (AIDS) in the human population, is a member of the genus Lentivirus in the 
family Retroviridae.  HIV-1 is primarily transmitted through heterosexual contact, although 
injection drug use, men who have sex with men (MSM) and mother-to-child transmission also 
constitute a considerable fraction in some countries.  Currently, there are an estimated 37 million 
people living with HIV-1/AIDS worldwide and in 2007, there were 2.7 million new HIV 
infections and 2 million HIV-related deaths (1).  However, some regions of the world, notably 
sub-Saharan Africa, are more heavily affected by this devastating disease, accounting for 67% of 
all people living with HIV and 75% of AIDS deaths in 2007.  In addition to regional differences, 
the burden of HIV is disproportionately distributed among women and ethnic minorities.  In 
2007, women represented nearly half of all HIV-infected people worldwide (1) and in the United 
States, while African-Americans accounted for only 13% of the population in 2003, they 
represented approximately 49% of new HIV/AIDS diagnoses (2).  
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1.2 DYNAMICS OF HIV/SIV INFECTION 
HIV-1 and pathogenic SIV infection are characterized by three major phases: primary infection, 
an asymptomatic or chronic phase, and a symptomatic phase or AIDS. Primary infection is 
defined by a massive increase in plasma viral load and loss of CD4+ T cells followed by a 
decrease to a viral load set-point associated with the initiation of antiviral immune responses.  
Within 1-2 weeks of SIV infection (3, 4) or 4-6 weeks post-HIV infection (5, 6), direct viral 
infection leads to the massive and selective loss of CD4+ T cells within the mucosa-associated 
lymphoid tissues (7) independent of the route of transmission (3, 8, 9).  Following this massive 
loss, acute infection in both humans and macaques is resolved with the onset of antigen-specific 
immune responses (10-13), encompassing the asymptomatic or chronic phase of infection.  
Eventual progression to the symptomatic phase or AIDS occurs after CD4+ T cell depletion 
accompanied by a variety of opportunistic infections, hematological and sometimes neurological 
disorders (14).  Due to the similarities between HIV-1 infection of humans and pathogenic SIV 
infection of macaques, the rhesus macaque/SIV model is well suited for the study of HIV 
pathogenesis (15).   
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1.3 DENDRITIC  CELL SUBSETS 
Dendritic cells (DC) are a heterogeneous population of bone marrow-derived antigen-presenting 
cells important in both innate and adaptive immune responses.  DC are present in different stages 
of maturation in blood as well as in lymphoid and non-lymphoid organs (16).  DC can be 
subdivided into two major subsets based on the lack of expression for markers of T cells (CD3), 
B cells (CD19 or CD20), monocytes (CD14), and natural killer cells (CD56), collectively 
referred to as Lineage-negative, and positive expression of the class II major histocompatibility 
complex (MHC II) specifically human leukocyte antigen (HLA)-DR.  In humans and rhesus 
macaques, the two main DC types are defined as CD11c+CD123¯ myeloid or ‘conventional’ DC 
(mDC) or CD11c¯CD123+ plasmacytoid DC (pDC).  
   
1.3.1 Myeloid DC 
1.3.1.1 General characteristics 
Myeloid DC (mDC) are central to generating T cell responses to invading pathogens (16).  In 
humans, mDC are defined as Lineage-negative (Lin¯, CD3¯ CD14¯ CD20¯CD56¯) HLA-DR+ 
cells expressing the integrin CD11c, and are similarly defined in rhesus macaques (17).  mDC 
are mainly derived from myeloid progenitor cells in bone marrow and treatment of humans and 
rhesus macaques with fms-like tyrosine kinase 3-ligand (Flt3-L) in vivo dramatically increases 
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the number of circulating mDC (17-19).  However, under inflammatory conditions monocytes in 
blood can give rise to cells with phenotypic and functional features of DC (20-23) but in the 
steady state, DC do not seem to be derived from monocytes, with circulating immature mDC 
distinguished from monocytes (21, 23, 24).  In humans and rhesus macaques, circulating mDC in 
blood are phenotypically immature based on low level expression of the costimulatory molecules 
CD86 and CD40 as well as undetectable CD80 expression (17, 19, 25).  
 
In addition to circulating in blood, mDC populate peripheral tissues such as skin and mucosa as 
immature cells capable of capturing and processing antigens (16). Following exposure to an 
invading pathogen, inflammatory mediators induce DC to mature and migrate from peripheral 
tissues to lymph nodes via afferent lymphatics and stimulate T cells to generate adaptive 
immunity.  The movement of DC into peripheral tissues and localization in lymph nodes is 
controlled by chemokine receptors and their ligands.  Immature mDC express CC chemokine 
receptors CCR1, CCR2, CCR5, and CCR6 which bind inflammatory chemokines responsible for 
recruiting DC to inflamed tissues (26, 27).    Upon maturation, DC express CCR7 conferring 
responsiveness to the lymph node-homing chemokines CCL19 (macrophage inflammatory 
protein 3β) and CCL21 (6Ckine), permitting appropriate localization of DC to the lymph node 
paracortex for interaction with T cells (27-29).  Lymph nodes draining peripheral tissues contain 
a population of phenotypically mature DC not found in blood, spleen or thymus (30).  In the 
steady state of mice and humans, most lymphoid organ DC display a mature phenotype, 
expressing the highest levels of HLA-DR, the maturation marker CD83 and costimulatory 
molecules CD80, CD86 and CD40 (30-32).  In humans, migratory DC in lymph nodes 
originating from Langerhans cells are identified by expression of CD1a and Langerin (33, 34).  
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Finally, Langerhans cells or skin-migratory DC in humans do not produce IL-12p70 but rather 
induce T-helper type 1 responses through production of IL-23 (35-37). 
1.3.1.2 mDC depletion during HIV and SIV infection   
 
Numerous studies have reported reductions in the number of mDC circulating in the blood of 
HIV-1 infected individuals (38-44).  mDC depletion occurs as early as 4 weeks following HIV 
infection, although data are conflicting (38, 45) and in anti-retroviral treatment-naïve patients, 
mDC numbers remain below pre-infection levels.  Nevertheless, recovery of mDC numbers can 
be achieved using anti-retroviral therapy, although results have been conflicting concerning the 
extent of recovery compared to uninfected controls (38, 42, 44, 46-48).  In cynomolgus 
macaques with chronic SIV infection, absolute numbers of CD1c+ mDC in blood were similar to 
uninfected controls, suggesting mDC loss may be limited to a specific mDC subset (49).     
 
1.3.1.3 mDC alterations in lymphoid tissue during HIV/SIV infection 
A central hypothesis for the loss of circulating mDC during HIV infection has been recruitment 
of mDC to lymph nodes, based on the bystander maturation of DC by pDC (50). However, the 
effects of HIV/SIV infection on the frequency and phenotype of mDC in peripheral lymph nodes 
is limited and often conflicting.  During acute HIV infection, in situ analysis of peripheral lymph 
nodes indicated an accumulation of DC-SIGN+ and CD40+ DC (51).  In SIV-infected 
cynomolgus macaques, migratory CD1a+ persisted in lymph nodes despite disease progression 
associated with decreases in mature CD83+ DC, suggesting simian AIDS may lead to impaired 
DC maturation.  However, in SIV-infected rhesus macaques with AIDS, decreases in mature 
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CD83+ DC was associated with loss of these cells from lymphoid tissues and linked to failed 
migration of Langerhans cells following contact sensitization (52).  More recently, mDC with a 
partial activation phenotype accumulated in lymphoid tissues during asymptomatic chronic HIV-
1 infection (53), although this study excluded migratory DC and may reflect recruitment of 
blood-derived mDC.  Therefore, the recruitment of mDC to lymph nodes during HIV or SIV 
infection remains incompletely defined.  
1.3.2 Plasmacytoid DC 
1.3.2.1 General characteristics 
Plasmacytoid DC (pDC) are relatively rare, innate immune system cells that play a critical role in 
the host response to viral infection.  In humans, pDC are phenotypically defined as lineage-
negative (CD3¯CD14¯CD20¯CD56¯CD16¯) HLA-DR+ cells expressing high levels of CD123 
(IL-3Rα) and equivalent pDC have been identified in rhesus macaques (17, 49, 54).  pDC are 
derived from hematopoietic progenitor cells in the bone-marrow and enter the bloodstream as 
end-stage non-dividing cells (55).  Administration of hematopoietic growth factors such as Flt3-
L in vivo leads to dramatic increases in the number of pDC in human blood and rhesus macaque 
blood and lymphoid tissues (17-19, 56), highlighting the hematopoietic origin of pDC. 
 
Under homeostatic conditions, pDC circulate in the blood and are located in peripheral lymphoid 
tissues (17, 31, 32).  However, pDC may also be found in non-lymphoid sites during 
inflammatory conditions such as cutaneous lupus erythematosus (57), allergic rhinitis (58), and 
contact dermatitis (59).  In blood, pDC are characterized as immature cells expressing low to 
undetectable levels of the co-stimulatory molecules CD86 and CD40 (25) and upon arrival in 
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lymph nodes acquire a mature phenotype with homogeneously high expression of CD40 (31).  
pDC emigration from blood to lymph nodes is controlled by chemokines.  In general, pDC 
express a multitude of chemokine receptors such as CCR5, CXCR3, CXCR4, and CCR7 (60).  In 
the steady state, pDC migrate to lymph nodes via high endothelial venules (HEV) using the 
CXCR4 ligand SDF-1/CXCL12 and L-selectin (CD62L - peripheral lymph node addressin) (61). 
Following inflammation, pDC are rapidly mobilized and recruited to inflamed lymph nodes in a 
CXCR3-dependent manner corresponding to increased expression of the interferon –γ –inducible 
chemokines Mig/CXCL9 and IP-10/CXCL10 (62, 63).  pDC activation through pathogen 
sensing or CD40 ligation, leads to the upregulation of functional CCR7 and responsiveness 
towards the chemokines SLC/CCL19 and ELC/CCL21, thereby localizing pDC in T cell-rich 
areas of lymph nodes (63).   
1.3.2.2 Role of pDC in viral immunity 
 
pDC are the most potent producers of anti-viral type I IFN, mainly IFN-α (62, 64, 65). IFN-α is 
produced by pDC in response to a wide variety of pathogens, including enveloped viruses such 
as herpes simplex virus (65), influenza virus (66, 67), HIV-1 and SIV (68, 69), as well as 
parasites (70) and DNA containing unmethylated CpG sequences typical of microbial DNA (62, 
65).  The ability of pDC to secrete IFN-α in response to such a vast array of pathogens is mainly 
through the detection of distinct pathogen-associated molecular patterns by the pattern 
recognition receptors Toll-like receptor (TLR) 7 and TLR9 (71).  TLR7 recognizes single-
stranded RNA and synthetic imidazoquinoline compounds, used in the treatment of human 
papilloma virus infections (71, 72).  TLR9 recognizes unmethylated CpG-oligodeoxynucleotide-
containing DNA such as the CpG-rich DNA viral genomes of herpes simplex viruses (HSV) 1 
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and 2 as well as mouse cytomegalovirus (71).  In addition to type I IFN, pDC produce TNF-α 
and a broad range of other proinflammatory cytokines upon activation and are the major DC 
subset in lymph nodes innately producing cytokines (32, 73). 
 
pDC-derived type I IFN directly controls virus infection in murine coronavirus and HSV models 
(74, 75).  Moreover, pDC-derived IFN-α is capable of limiting HIV replication in CD4+ T cells 
(76-78), highlighting the role of pDC in controlling HIV infection.  Live or replication defective 
HIV-1 viral binding via CD4 mediates endocytosis of HIV and endosomally delivered viral RNA 
stimulates type I IFN production by pDC through TLR7 (79), indicating pDC activation occurs 
independent of direct viral infection. 
 
pDC play a central role in activating host innate and adaptive immune responses.  pDC activation 
results in both direct and/or indirect activation of many other cell types, including mDC, NK 
cells, and T cells.  pDC exposure to HIV-1 induces the phenotypic maturation of pDC and 
upregulation of functional CCR7, with IFN-α production resulting in bystander maturation of 
mDC, which are not activated directly by HIV-1 (50).  In addition, pDC help lymph node DC to 
induce robust virus-specific T cell responses (80) and increase NK cell-mediated cytotoxicity, 
IFN-γ production and early anti-viral resistance (81).  pDC-derived IFN-α also provides an 
important signal for T helper precursor differentiation in favor of a T helper type 1 immune 
response (82) and directly amplifies CD8+ T cell expansion after viral infection (83). 
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1.3.2.3 pDC depletion and dysfunction during HIV and SIV infection 
 
pDC are depleted in blood during both HIV and SIV infection (38, 43, 44, 46, 47, 49, 54, 84-87), 
which is correlated with high viral load and the occurrence of opportunistic infections and 
Kaposi sarcoma (87).  In primary HIV infection, pDC are lost in parallel with CD4+ T cells in 
blood and is inversely correlated with plasma viral load while in chronic HIV infection, pDC loss 
from blood is correlated with clinical state and predictive of disease progression (41-43, 46).  
Even in pediatric patients, pDC counts are lower in viremic children with declining CD4+ T cells 
compared to children with stable CD4+ T cell counts (88).  Administration of highly active anti-
retroviral therapy (HAART) leads to at least partial recovery of pDC counts in peripheral blood 
during primary and chronic HIV infection (41, 42, 44, 46, 47) and often correlated with CD4 
count recovery and decreased viral loads.  Similarly, pDC are depleted in both blood and 
lymphoid tissues in rhesus, cynomolgus and pig-tailed macaques with chronic SIV infection and 
AIDS (49, 54, 85) and this loss is inversely correlated with plasma viremia (54).  In contrast, 
nonpathogenic SIV infection of African green monkeys results in early pDC loss during acute 
infection followed by a return to normal frequencies during the chronic stage of infection (89).  
Recent evidence indicates that pDC numbers increase in the blood of SIV-infected macaques 
within the first week of infection (84), consistent with their early role in limiting viral infection 
(90).  However, pDC numbers were significantly depleted through the remaining period of 
observation in SIV-infected macaques (54, 84). 
 
In addition to the reduced frequencies of pDC in blood during HIV infection, functional defects 
have also been observed.  In individuals with chronic HIV infection, loss of pDC numbers in 
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blood are correlated with decreased IFN-alpha production (91) and pDC from HIV-infected 
individuals are less responsive to TLR9 stimulation in vitro (46, 91-94).  Recently, it has been 
suggested that diminished pDC responses in HIV-infected patients is a consequence of prior 
activation via type I IFN or HIV virions (93).  Together, these findings suggest reductions in 
both pDC frequency and function lead to inadequate control of HIV. 
1.4 POTENTIAL MECHANISMS OF DC LOSS DURING HIV AND SIV INFECTION 
1.4.1 Direct viral infection of DC 
pDC in both humans (41, 68, 87, 95, 96)  and macaques (49, 54) express the viral receptor CD4 
and co-receptors CCR5 and CXCR4 making them likely targets of HIV infection.  In vitro, pDC 
can be infected with both CCR5 and CXCR4-tropic strains of HIV-1 (68, 95-98) and 
preferentially transmit virus to antigen-specific CD4+ T cells (99).  pDC isolated from HIV-
infected patients show evidence of direct infection (40) and pDC in tonsils and thymus of HIV-
infected patients were found containing the HIV p24 antigen, indicating pDC can be 
productively infected by HIV in vivo (96).    
 
Similar to pDC, both humans and macaque immature blood mDC and Langerhans cells in skin 
express the main viral receptor, CD4, as well as the co-receptor CCR5 (49, 52), implicating 
mDC may be directly infected with virus.  In support of this observation, in vitro exposure of 
mDC to HIV leads to maturation and infection (96, 98) and recent findings demonstrate evidence 
of infection in vivo (40).  Moreover, mDC infected in vitro preferentially transmit virus to 
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antigen-specific CD4+ T cells (99).  However, in patients treated with HAART and undetectable 
plasma viral RNA, neither proviral DNA or viral RNA was found in either mDC or pDC, 
indicating direct infection may not play a role in DC depletion during aymptomatic infection 
(100).  Together, these findings indicate direct viral infection may play a role in the loss of mDC 
during HIV/SIV infection. 
1.4.2 DC recruitment to lymphoid tissues 
One of the major mechanisms proposed for the loss of circulating DC has been redistribution to 
lymphoid tissues.  pDC exposure to HIV in vitro leads to activation and up-regulation of the 
chemokine receptor CCR7 (50, 101, 102) responsible for pDC localization to the T-cell rich 
lymph node paracortex.  In addition, pDC activation via HIV leads to the bystander maturation 
of mDC(50).  Notably, CCR7 binds to the inflammatory chemokine MIP-3β/CCL19 which is 
increased during acute SIV infection.  pDC in blood express CXCR3 which binds to the 
inflammatory chemokines IP-10/CXCL10 and Mig/CXCL9 (62), and pDC recruitment to 
inflamed lymph nodes occurs in a CXCR3-dependent manner (63).  In pathogenic SIV infection 
of rhesus macaques, the inflammatory chemokines for CXCR3 are increased in lymphoid tissues 
during both acute and chronic infection (103, 104).  Therefore, there is ample evidence 
implicating DC recruitment to lymphoid tissues during HIV and SIV infection.   
1.4.3 Bone marrow suppression 
DC are derived from bone marrow progenitor cells (24) and reductions in hematopoietic 
progenitor cells have been reported in bone marrow during HIV (105-107) and SIV infection 
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(108-110).  Nevertheless, hematopoietic progenitor cells are relatively resistant to HIV with 
minor frequencies infected in vitro and in vivo (111).  In addition, CD34+ hematopoietic stem 
cells are resistant to HIV infection despite expression of the viral receptors CD4, CCR5 and 
CXCR4 (112).  Bone marrow stroma plays a critical role in the development and maintenance of 
hematopoiesis indicating stromal dysfunction may lead to alterations in hematopoiesis.  In rhesus 
macaques, stromal cells express low levels of CD4 and CCR5 and could be infected with SIV in 
vitro, but infected stromal cells were not found in vivo (113).  Perhaps most importantly, SIV-
infected macaques treated with a chimeric Flt3-L and G-CSF receptor agonist, effectively 
increased both mDC and pDC in blood (114), suggesting bone marrow suppression is not likely 
to be a significant factor in DC loss.   
1.4.4 Bystander apoptosis of DC 
Another potential mechanism for the loss of DC during HIV and SIV infection is through 
bystander apoptosis, a well-described mechanism of T cell loss in HIV and SIV infection (115-
119).  In HIV-infected individuals, the majority of apoptotic T cells in peripheral blood and 
lymph nodes are uninfected (117-121) and in SIV-infected macaques, apoptosis occurs 
predominately in bystander cells (116).  The extrinsic pathway of apoptosis is initiated by 
binding of TNF family ligands to cognate death receptors, classically involving Fas-ligand 
(FasL) binding to Fas, and numerous studies indicate a role for Fas/FasL in apoptosis of T cells 
in HIV infection (122-124) and progressive SIV infection (125).  Interestingly, binding of FasL 
to Fas induces the maturation of healthy DC, not death (126).  However, Fas-mediated pathways 
have been implicated in DC apoptosis during measles virus infection (127), suggesting the DC 
response to Fas may altered in SIV infection.  pDC in human tonsils express Fas, however pDC 
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from both uninfected and HIV-infected individuals were equally susceptible to FasL-induced 
apoptosis (78).  Nevertheless, spontaneous apoptosis mediates the depletion of mDC and pDC in 
the blood of patients with breast cancer (128, 129).  Collectively, the ultimate role of apoptosis in 
DC loss during HIV and SIV infection remains to be determined. 
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2.0  HYPOTHESIS AND SPECIFIC AIMS 
Dendritic cells (DC) are professional antigen-presenting cells essential for the induction of both 
innate and adaptive immune responses to pathogens.  The two major DC subsets described in 
humans, mDC and pDC are found in blood as well as in non-lymphoid and lymphoid tissues at 
low frequencies.  It has been well described that mDC and pDC are lost from the circulation in 
human immunodeficiency virus type 1 (HIV-1)-infected individuals, associated with progression 
to disease and related to increased viral loads and reduced numbers of CD4+ T cells.  It has been 
suggested that the loss of DC from blood may be due to an increased recruitment in lymphoid 
tissues, direct destruction due to viral infection, or bone marrow suppression.  We hypothesized 
that SIV infection causes a dysregulation of DC trafficking and death not solely dependent 
upon direct viral infection.  In order to address this multifactorial hypothesis, we proposed 
three specific aims: 
1) Characterize DC in blood and develop a rapid assay for DC enumeration.  
DC subsets in blood were phenotypically characterized with particular focus on 
lineage markers followed by development of a rapid assay for DC enumeration 
from small volumes of blood.   
 
2)  Determine whether DC are recruited to or lost from lymphoid tissues in 
simian AIDS.  DC numbers in blood and lymphoid tissue were quantified and 
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changes in costimulatory molecule expression was performed.  In addition, DC in 
lymphoid tissues were examined for changes in spontaneous cell death as an 
additional mechanism of DC loss.   
 
3) Determine whether pDC redistribution to lymphoid tissues, lack of 
production and mobilization, or direct viral infection leads to loss from blood 
during acute SIV infection.  Changes in blood pDC numbers were monitored at 
frequent intervals during the first 14 days of SIV infection in addition to in vivo 
BrdU labeling and Ki-67 analysis to measure DC mobilization in SIV-naïve 
controls and animals with acute SIV infection.  pDC frequencies were determined 
in bone marrow, blood and peripheral lymph nodes using flow cytometry  and 
real-time RT-PCR used to determine the frequency of infected DC in lymph 
nodes from SIV-infected monkeys.  Alterations of pDC function were determined 
using a TLR7/8 agonist and assessment of intracellular TNF-α and IFN-α by flow 
cytometry. 
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3.0  CHAPTER ONE.  IDENTIFICATION AND RAPID DUAL-PLATFORM 
ENUMERATION OF PLASMACYTOID AND CD16+ MYELOID DENDRITIC CELLS 
IN RHESUS MACAQUES 
3.1 PREFACE 
This chapter is adapted from a submitted manuscript (Kevin N. Brown1,2 and Simon M. Barratt-
Boyes1,2,3.  Work described in this chapter and is in fulfillment of specific aim 1.   
 
1Department of Infectious Diseases and Microbiology, Graduate School of Public Health, and 
2Center for Vaccine Research and 3Department of Immunology, School of Medicine, University 
of Pittsburgh,  Pittsburgh, PA 15261, USA. 
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3.2 ABSTRACT 
Dendritic cells (DC) are a heterogenous population of antigen presenting cells important in the 
control of innate and adaptive immune responses.  Non-human primates are increasingly used for 
disease, transplantation, and vaccine trial studies, and contribute to our understanding of the role 
of DC in immunity.  However, DC in rhesus macaques have been variably defined in peripheral 
blood by exclusion using lineage-specific lymphocyte markers leading to discrepancies in both 
their identification and enumeration.  To better understand the phenotypic complexity of rhesus 
DC, we undertook a multi-parameter analysis of DC in blood and developed a rapid assay for 
enumeration.  Flow cytometric analysis of DC in blood revealed nearly 100% of myeloid DC 
(mDC) expressed CD16 but not CD8 and moderate levels of both CD11b and CD56.  In contrast, 
plasmacytoid DC (pDC) were phenotypically homogenous.  In whole blood samples, 
simultaneous discrimination of mDC and pDC was inconsistent and resolved by first lysing red 
blood cells and washing followed by immunophenotypic analysis.  Dual-platform analysis 
relying on mononuclear cell counts and the frequency of DC determined by flow cytometry from 
small volumes of RBC-lysed blood, averaged 50.0 mDC/μL and 2.5 pDC/μL of blood in normal 
rhesus macaques.  This study provides evidence that rhesus mDC are more phenotypically 
homogenous than human mDC.  In addition, information regarding the phenotypic complexity of 
rhesus macaque DC and their rapid enumeration may improve our understanding of the role of 
these cells in infectious disease. 
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 3.3 INTRODUCTION 
Dendritic cells (DC) are a heterogenous population of antigen-presenting cells (APC) important 
in the control of innate and adaptive immune responses (16).  In the blood of humans and rhesus 
macaques, two major populations of DC have been described; CD11c−CD123high plasmacytoid 
DC (pDC) and CD11c+CD123low myeloid or ‘conventional’ DC (mDC).  Human DC are 
traditionally identified based on the expression of HLA-DR and lack of expression of lineage 
markers CD3 (T cells), CD14 (monocytes), CD19 or CD20 (B cells), and CD16 or CD56 
(natural killer cells) (65).  More recently however, human CD11c+ mDC circulating in blood 
were phenotypically subdivided into three additional subsets based on expression of  CD16, 
CD1b/c, and BDCA-3 (25).         
 
Despite the well characterized delineation of multiple DC subsets and lineage markers used in 
humans, studies of rhesus macaque DC have not reached a consensus regarding the use of 
standardized lineage markers (17, 19, 54, 85, 114, 130).  In rhesus macaques, immature 
monocyte-derived DC have been shown to express moderate levels of CD11b, CD56 and CD16 
suggesting mDC in blood may exhibit a similar phenotypic profile (131) and rhesus mDC have 
been subdivided based on CD11b expression (114).  In addition, a minor subset of CD8+ cells 
has been identified within the Lin−HLA-DR+ fraction of rhesus blood suggesting some mDC 
may express CD8 (19).  Furthermore, flow cytometric analysis of rhesus blood for candidate NK 
cells revealed an undefined population of cells that were CD3−CD8−CD20−/dimCD16bright (132), 
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leaving open the possibility that mDC express CD16 similar to humans (25).  Lastly, a small 
number of CD14¯CD56dim cells accounting for less than 2% of lymphocytes and lacking NK cell 
associated lytic activity was observed in rhesus macaques (133).  Therefore, it is imperative that 
the phenotypic complexity and overlap between rhesus DC and cellular populations such as 
monocytes and NK cells be addressed to increase our understanding of circulating cells in the 
peripheral blood of rhesus macaques.   
 
Enumeration of DC subsets in the blood of both humans and rhesus macaques is gaining 
increased interest, particularly in studies of human immunodeficiency virus (HIV)(38, 39, 41-43, 
46, 47, 87) and simian immunodeficiency virus (SIV) infection(49, 54, 85).  Although 
considerable progress has been made towards developing rapid assays for evaluating CD4+ T cell 
numbers (134), standardization of DC counting has been lacking.  Historically, the most widely 
used method for DC and CD4 enumeration has been dual-platform analysis.  Using this strategy, 
the total or absolute number of cells in blood is obtained from three clinical measurements; a 
white blood cell count, lymphocyte and monocyte percentage (differential), and a DC or CD4+ T 
cell percentage using flow cytometric immunophenotyping.  Alternatively, single-platform 
technologies determine absolute cell numbers in unmanipulated blood in a single tube containing 
a known number of fluorescent beads.  Although considerable progress has been made towards 
using single-platform counting methods for evaluating CD4+ T cell numbers (134), investigation 
of rapid assays for the enumeration of DC are limited (49, 135, 136).  
 
In this study, circulating rhesus CD11c+ mDC were uniformly CD16+ CD11b+ CD56lo CD8– 
CD1c– whereas CD123+ pDC lacked expression of all these markers. Accurate DC counts were 
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obtained using a rapid dual-platform assay combining TruCOUNT enumeration of mononuclear 
cells in whole blood and multiparameter analysis of DC in peripheral blood leukocytes (PBL). 
3.4 MATERIALS AND METHODS 
3.4.1 Reagents 
Antibodies were purchased from BD Biosciences (San Diego, CA) unless noted otherwise: CD3 
(SP34), CD4 (L200), CD45 (DO58-1283), CD14 (M5E2), CD20 (2H7, eBioscience), HLA-DR 
(L243), CD123 (7G3), CD11c (S-HCL-3), CD16 (3G8 and VEP13, Miltenyi Biotec), CD56 
(MY31), CD11b (D12 and ICRF44), CD8α (B9.11, Coulter), CD33 (AC104.3E3, Miltenyi 
Biotec), and CD1c (AD5-8E7, Miltenyi Biotec).   
3.4.2 Animals and blood collection 
Peripheral blood samples were collected in EDTA (K2E) and ACD Vacutainers and processed 
within 4 h of collection from healthy adult rhesus macaques (Macca mulatta) of either sex.   
Complete blood cell counts were performed by an automated hematology blood analyzer 
approximately 24 h after blood collection by an outside vendor (Antech Diagnostics, Lake 
Success, NY).  All procedures were approved by the University of Pittsburgh Instituitional 
Animal Care and Use Committee. 
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3.4.3 Sample preparation 
Peripheral blood mononuclear cells (PBMC) were isolated from ACD-collected blood for rhesus 
macaques and human buffy coats by density gradient centrifugation over Histopaque-1077 
(Sigma).  In addition, rhesus PBMC depleted of CD14+ monocytes were also used and 
designated as CD14-negative (CD14¯) PBMC.  Alternatively, 50 or 100 µL EDTA-collected 
whole blood was treated with 1 or 2 mL ACK lysing buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 
mM Na2EDTA in dH2O, pH: 7.2 – 7.4), respectively, for 10 min at room temperature, 
centrifuged and washed two times with staining buffer prior to the addition of mAb. 
3.4.4 TruCOUNT assay  
For single-platform TruCOUNT analysis, 50 μL (T cells) or 100μL (DC) of reverse pipetted 
EDTA-collected peripheral blood was stained directly with mAb mixtures for 15 min at room 
temperature followed by the addition of 450μL (T cells) or 900μL (DC) BD FACS Lysing 
Solution for 15 min at room temperature, placed at 4ºC and analyzed within 4 h.   
3.4.5 Flow cytometry 
TruCOUNT determination of MNC, CD4+ T cells and DC  was performed by setting the 
cytometer threshold on CD45-PerCP fluorescence and acquiring at least 2,500 CD45+CD3+CD4+ 
T cell events and 10,000 HLA-DR+ events for DC analysis.  For TruCOUNT and dual-platform 
analysis using PBL, CD4+ T cells were identified using CD45-PerCP, CD3- Pacific Blue and 
CD4-FITC and DC were stained with the following panel:  Pacific Blue-conjugated anti-CD3, 
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CD14, and CD20 (Lineage), HLA-DR-FITC, CD45-PerCP, CD123-PE, and CD11c-APC.  For 
analysis of mDC and pDC in PBMC or CD14¯ PBMC, cells were stained with Pacific Blue-
conjugated lineage markers, HLA-DR-PerCP, CD11c-APC and PE-conjugated CD11b, CD56, 
CD33, and CD16 or FITC conjugated CD8α and CD1c or CD11b-Alexa488.  Expression of 
additional markers on pDC was determined as above except pDC were labeled using CD123-
biotin followed by 20nM streptavidin QDot525 (Invitrogen) incubated at 4ºC for 25 min.  
Analysis of markers with possible low expression levels was determined using flow minus one 
(FMO) controls where all parameters used to define gated populations were included except for 
the antibody of interest (137).  1 - 4 x 106 cells were stained followed by incubation with a blue 
fluorescent amine-reactive viability dye (Invitrogen) for exclusion of dead cells, per the 
manufacturer’s instructions.  PBMC and PBL samples were fixed in 1% paraformaldehyde, kept 
at 4°C and analyzed within 4 h.  For evaluation of lineage markers on DC, stopping gates were 
set at 1,000 mDC events or a minimum of 500 pDC events.  For DC analysis in RBC-lysed blood 
(PBL) stopping gate was set at a minimum of 50 pDC events.  For analysis of human PBMC, 
CD11c+ mDC were defined as Lin¯ (CD3, CD14, CD20, CD56, CD16) HLA-DR+ CD11c+ cells 
and monocytes as CD14+HLA-DR+.  Data was collected on a BD LSRII and analyzed using BD 
FACSDiva software version 5.0.2. Histogram overlays were generated using FlowJo software 
version 7.4.2 (Tree Star, Ashland, VA).  
3.4.6 Statistical analysis 
Statistical analysis was perfomed using GraphPad software (San Diego, CA).  Differences 
between counting methods were determined using the nonparametric paired Wilcoxon rank sum 
test.  Two-tailed P values < 0.05 were considered significant.    
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3.5 RESULTS  
3.5.1 Rhesus macaque myeloid dendritic cells express CD16, CD11b and CD56 
In order to investigate the phenotypic complexity of rhesus macaque DC, we focused on defining 
the basic phenotypic profile of both mDC and pDC using comparative analysis to monocytes and 
NK cells by flow cytometry.  DC subsets were simultaneously identified in PBMC as CD3, 
CD14, and CD20-negative (Lineage¯) HLA-DR+ CD11c+CD123¯ mDC or CD11c¯CD123+ 
pDC (Fig. 1A).  Rhesus pDC were phenotypically homogeneous and lacked expression of 
CD11b, CD56, CD8 and CD16, consistent with human pDC (25).  However, approximately 50% 
of CD11c+ mDC expressed moderate levels of CD11b and CD56 (Fig. 1C) compared to 
monocytes (Fig. 1D).  Strikingly, nearly 100% of circulating mDC expressed CD16 with an 
intensity similar to rhesus NK cells (Fig. 1, C and D) and an alternative anti-CD16 mAb 
(VEP13) provided comparable results (data not shown).  In addition, evaluation of an alternative 
CD11b clone (ICRF44) showed staining of a higher percentage of mDC (Fig. 1E).  Overall, 
CD11c+ mDC were 53-85% CD11b+, depending on the mAb used, followed by 53% CD56+ and 
96% CD16+ (Fig. 1E).  Collectively, inclusion of all DC in rhesus peripheral blood is achieved 
using the standard lineage markers, CD3, CD14, and CD20. 
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 Figure 1. Rhesus macaque CD11c+ mDC express CD11b, CD56 and CD16 
A, Representative contour plots demonstrate the gating strategy used to define mDC and pDC in total PBMC or 
CD14¯ PBMC.  DC were identified within the CD3/14/20-negative HLA-DR+ fraction of live mononuclear cells 
(R3) as either CD11c+ mDC or CD123+ pDC.  B, Phenotypic profile of CD123+ pDC and (C) CD11c+ mDC. 
D, Expression level of each phenotypic marker by rhesus monocytes (CD14+ HLA-DR+) and   natural killer (NK) 
cells (CD3/14/20-negative HLA-DR-negative).  Histograms for each marker (filled histograms) are shown with 
respective isotype-matched control antibody (dashed lines).  Histograms are representative of five (mDC) and two 
(pDC, monocytes, NK cells) experiments from different animals.  E,  Expression of the indicated markers and mAb 
clones (CD11b) by CD11c+ mDC.  **P < 0.01.  Symbols represent individual animals and horizontal bars represent 
the median.   
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3.5.2 Phenotypic characterization of rhesus CD16+ mDC 
The finding that 50% of mDC expressed CD11b and CD56 led us to evaluate whether these 
markers may separate mDC into non-overlapping CD11b+CD56¯ and CD11b¯CD56+ subsets.  
In order to investigate this hypothesis, mDC were simultaneously stained with CD16, CD11b 
and CD56 (Fig. 2A).  Based on the limited availability of directly conjugated cross-reactive 
mAbs, we used the CD11b clone ICRF44, which stains a greater percentage of mDC than clone 
D12 (Fig. 1E).  Interestingly, the majority of CD11c+ CD16+ mDC were CD11b+CD56+ and 
CD11b+CD56¯ (Fig. 2, A and B).  Therefore, CD11c+CD16+ mDC are heterogeneous for CD11b 
and CD56 with no clear evidence that these markers define non-overlapping mDC subsets.   
 
In a recent study, CD1c was used to identify mDC in cynomolgus macaques and reported to 
cross react with rhesus PBMC (17, 49).  Within the Lineage¯ HLA-DR+ fraction, there was no 
evidence of CD1c expression by either CD11c¯ or CD11c+ mDC.  Parallel analysis revealed 
CD1c was expressed by approximately 30% of B cells (Fig. 2C), similar to humans (138).  
Evaluation of whether CD33 would further subdivide mDC revealed CD33 reactivity was 
restricted to rhesus granulocytes with low levels of expression similar to human monocytes (Fig. 
2D).  However, in contrast to humans, rhesus mDC and monocytes completely lacked CD33 
expression (Fig 2D).  Therefore, rhesus mDC lack expression of CD33 and CD1c but nearly all 
are CD16+ and phenotypically heterogenous with respect to CD11b and CD56 expression.   
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 Figure 2. Overlapping subsets of CD11b+ and CD56+ mDC. 
A, Plots demonstrate the gating strategy used to define subsets of CD16+ mDC.  B, Symbols represent individual 
animals and horizontal bars represent the median.  C, Representative contour plots of CD1c expression by CD20+ B 
cells and the Lin¯HLA-DR+ fraction of rhesus PBMC (n=4).  mDC are CD11c+.  D, Expression profile of CD33 on 
rhesus macaque granulocytes (CD45+SSChigh), and rhesus or human mDC and monocytes (CD14+HLA-DR+).  
Histogram overlays are representative of two rhesus and two human samples.  Dashed lines represent the level of 
background staining using the appropriate isotype control. 
 
3.5.3 RBC-lysis yields increased mDC and pDC discrimination in whole blood 
Having evaluated the expression of additional lineage markers by mDC in PBMC we sought to 
determine whether a single-platform cell counting technology could be used to simultaneously 
quantify both mDC and pDC subsets in undiluted blood from rhesus macaques.  Using BD 
TruCOUNT® tubes, the presumptive DC fraction was identified by sequential gating similar to 
the analysis of PBMC (Fig. 3A).  Specifically,   mononuclear cells (MNC) containing both 
lymphocytes and monocytes were defined as CD45+side-scatter (SSC)low and DC identified 
within the CD3, CD14, CD20 (Lineage)-negative HLA-DR+ fraction of blood (Fig. 3A).  In 
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general, the delineation of Lin¯ from Lin+ cells was less pronounced in undiluted blood 
compared to PBMC (Fig. 3A).  In addition, the identification of CD11c+ cells within the Lineage-
negative HLA-DR+ fraction compared to isotype control staining was not well defined.  
However, CD123+ pDC were easily identified within the Lineage-negative HLA-DR+ fraction of 
undiluted blood, consistent with the findings of others (49).  As an alternative to the isolation of 
PBMC, we sought to determine whether the same small volume of blood used for TruCOUNT, 
first cleared of red blood cells (RBC) prior to mAb staining would permit clear discrimination of 
both mDC and pDC.  Strikingly, mDC and pDC were readily identified in samples cleared of 
RBC and washed prior to the addition of antibodies (Fig. 3B).  Comparatively, the distinct mDC 
and pDC populations were identified using either logarithmic or biexponential axis scaling, the 
latter permitting increased visualization of pDC (Fig. 3B, bottom panel).  The Lin¯HLA-DR+ 
fraction of RBC-lysed whole blood represented approximately 3.6% of mononuclear cells with 
the majority of cells being mDC (59%) followed by pDC (2.8%) (Fig. 3C), similar to previous 
findings in PBMC (17, 54, 85).  Therefore, RBC-lysis of small blood volumes prior to mAb 
staining permitted increased discrimination of both DC subsets in rhesus macaques. 
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 Figure 3. Increased DC subset discrimination in RBC-lysed whole blood. 
A, Representative contour plots demonstrate the gating strategy used to define DC in whole blood or (B) RBC-
lysed/washed blood samples.  Mononuclear cells (MNC) were gated based on CD45 and SSC followed by gating on 
the Lineage-negative HLA-DR+ fraction (Lin¯DR+).  mDC and pDC gates were determined using appropriate 
isotype controls.  The bottom panels in (B) illustrate biexponential scaling to delineate DC subsets. C, Percentage of 
cells within the indicated cellular fractions of RBC-lysed/washed blood samples from rhesus macaques (n = 9).  Box 
plots represent the 25th, 50th, and 75th percentiles and vertical lines represent the minimum and maximum values 
obtained. 
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3.5.4 Quantifying rhesus peripheral blood mononuclear cells using TruCOUNT 
Given the ease with which DC subsets were identified in RBC-lysed blood, we explored 
combining single-platform TruCOUNT technology with the percentage of cells within the MNC 
fraction of blood determined by flow cytometry.  First, we compared the absolute number of 
MNC in blood was compared using traditional complete blood cell counts (CBC) plus 
differential and gating of CD45+SSClow MNC in TruCOUNT (Fig. 4A).  Expectedly, there was 
no significant difference in the absolute number of MNC/μL of blood calculated using CBC 
results or BD TruCOUNT technology (Fig. 4B, P = 0.5418).  In order to validate an approach 
using MNC counts determined by TruCOUNT and the percentage of cells within RBC-lysed 
whole blood (PBL), we turned to CD4+ T cell enumeration.  Qualitatively, the separation of 
CD4+ T cells in PBL from other lymphocytes was increased compared to staining of undiluted 
whole blood (Fig. 4, A and C).  Notably, there was no significant difference in either the 
frequency or absolute number of CD4+ T cells in TruCOUNT or PBL samples (Fig. 4D).  Thus, 
PBL samples offered the advantage of increasing phenotypic discrimination of CD4+ T cells and 
more importantly, accurate enumeration of cells comparable to single-platform TruCOUNT 
technology. 
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 Figure 4. RBC-lysed whole blood permits accurate enumeration of CD4+ T cells. 
A, Dot plots demonstrate the gating strategy used to define mononuclear cells (MNC) and CD4+ T cells for 
TruCOUNT determination of absolute numbers in blood.  B, Absolute numbers of MNC were obtained using an 
automated hematology analyzer (CBC) and TruCOUNT technology.  Absolute number of cells was determined by 
including a gate for the number of counting beads.  Symbols represent individual animals and horizontal bars 
represent the median (n=10).  C, Dot plots demonstrate the gating strategy used to define MNC and CD4+ T cells in 
RBC-lysed PBL.  D,  Percentage and absolute number of CD4+ T cells was determined for the same sample using 
TruCOUNT and dual-platform analysis using PBL.  Symbols represent individual animals and horizontal bars 
represent the median.  No significant differences were found were B and D. 
3.5.5 Dual-platform quantitation of pDC and mDC in blood 
The success of accurately enumerating CD4+ T cells using RBC-lysed PBL combined with MNC 
counts determined by TruCOUNT led us to evaluate the utility of calculating absolute numbers 
of DC in the same manner.  Similar to our earlier analysis (Fig. 3B), the frequency of DC in PBL 
was determined by gating on CD45+SSClow MNC, Lin¯HLA-DR+ cells and finally 
CD11c+CD123¯ mDC or CD11c¯CD123+ pDC (Fig. 5A).  Using this dual-platform strategy, 
there were approximately 50 mDC/μL of blood in normal rhesus macaques (Fig. 5B).  For pDC, 
dual-platform enumeration yielded numbers similar to single-platform TruCOUNT, with 
approximately 2.3 pDC/μL of blood (Fig. 5C).  In order to quantify fluctuations in DC numbers, 
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four to six blood samples were obtained from each rhesus macaque over a 2 – 3 month period 
and enumerated using dual-platform analysis.  Both mDC and pDC showed inter-individual 
variability with more pronounced intra-individual variability in mDC (Fig. 5D).  Overall, the 
median absolute number of mDC was 50.1 cells/μL and 2.5 pDC/μL of blood (Fig. 5E), 
consistent with previous findings (17, 49, 54). 
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Figure 5. Dual-platform quantitation of rhesus DC subsets in blood. 
A, Representative contour plots demonstrate the gating strategy used to define DC subsets in RBC-lysed blood 
samples.  Mononuclear cells (MNC) were gated based on CD45 and SSC followed by gating on the Lineage-
negative HLA-DR+ fraction (Lin¯DR+) and CD11c+ mDC and CD123+ pDC.   B, Absolute numbers of mDC and 
pDC (C) were determined using freshly isolated whole blood (TruCOUNT) or RBC-lysed blood (PBL).  Absolute 
numbers of DC in PBL were determined by multiplying the percentage of DC within the MNC fraction by the 
absolute number of MNC.  Symbols represent individual animals and horizontal bars represent the median.  D, Four 
to six consecutive counts of mDC (left panel) and pDC (right panel) in individual rhesus macaques over a 2-3 month 
period.  The mean + SD is shown.  E, Absolute numbers of mDC and pDC were determined by combining the 
median number from the multiple measurements of each animal as shown in (D).  Box plots represent the 25th, 50th, 
and 75th percentiles and vertical lines represent the minimum and maximum values (n=9). 
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3.6 DISCUSSION 
The phenotypic complexity of DC subsets in both humans and rhesus macaques has led to 
considerable differences in DC identification and quantitation.  The main contributing factors to 
these differences are mainly the mAb mixtures used to define Lin¯ cells, isolation procedures, 
gating criteria for flow cytometric analysis and method of counting.  Although progress has been 
made in providing more definitive strategies for DC analysis in humans (25, 136), non-human 
primate research is lacking in this regard.  Therefore, we undertook an analysis of the 
composition of rhesus macaque Lin¯ cells in an effort to define the phenotypic heterogeneity of 
rhesus macaque DC.   In addition, we report that a dual-platform approach requiring simple 
RBC-lysis prior to mAb incubation provides a rapid assay for accurate assessment of absolute 
DC numbers comparable to previously used methods of DC enumeration.   
 
Our results demonstrate that all CD11c+ mDC in rhesus macaques are defined as CD3¯ 
CD14¯CD20¯ HLA-DR+ CD16+ and display heterogeneous expression of CD11b and CD56.  
The small number of CD14¯CD56dim rhesus lymphocytes lacking NK lytic function in previous 
studies (132, 139) may correspond to the CD56+ mDC reported here.  However, CD56 has been 
shown to be expressed by other cells within the Lin¯HLA-DR+ fraction of PBMC not accounted 
for by either mDC or pDC (17).  Interestingly, the cross-reactivity of the CD1c mAb used by us 
and others was restricted to rhesus B cells, consistent with humans.  In humans, CD1c is 
expressed by B cells and a subset of mDC (25, 138) and more recent evidence indicates CD1c is 
expressed by a subset of  Lin¯ HLA-DR+ cells in cynomolgus macaque with a phenotype and 
frequency consistent with CD11c+ mDC (49).  Nevertheless, CD123+ pDC were phenotypically 
homogenous consistent with previous findings in both humans and macaques (17, 25, 49, 85).  
 33 
 The finding that nearly all rhesus CD11c+ mDC express CD16 also provides considerable insight 
to immunophenotypic studies.  In a previous study delineating NK cell populations in rhesus 
macaques, a population of CD3¯CD8¯CD20¯CD16+ cells of unknown origin was found lacking 
expression of a panel of NK or B-cell markers and is likely the CD11c+CD16+ mDC reported 
here (132).  Furthermore, rhesus macaque NK cells in peripheral blood defined as CD3¯CD16+ 
would also include CD16+ mDC (140).  In contrast to CD8+ rhesus NK cells, CD16+ mDC do not 
express CD8, indicating NK cells are accurately defined as CD3¯CD8+CD16+ cells (132) and 
future studies of macaque DC may incorporate CD8 as an additional lineage marker to exclude 
NK cells within the Lin¯HLA-DR+ fraction of blood (49).   
 
Evaluation of performing single-platform counting of DC in rhesus macaques demonstrated poor 
immunophenotypic delineation and simultaneous identification of mDC and pDC.  The reason 
for the reduced resolution of phenotypically defined cellular subsets in undiluted blood is 
unclear, although less than optimal binding of anti-human specific mAb on cynomolgus macaque 
cells has been observed (49).  However, RBC-lysis and washing of cells prior to the addition of 
mAb increased the separation of discrete phenotypically-defined cellular subsets not only for DC 
but also CD4+ T cells.  This assay offers a rapid approach to study the phenotype of peripheral 
blood cells and should reduce the loss of cells associated with PBMC isolation requiring several 
washing steps prior to staining.  The dual-platform approach resulted in absolute numbers of 
mDC similar to previous findings in humans (136) and macaques (17, 49).  Interestingly, the 
absolute number of pDC determined using either single or dual-platform analysis was consistent 
with previous findings in rhesus macaques (17), but lower than pDC in either humans or 
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cynomolgus macaques (49, 136).  The reason for such a difference in pDC frequencies between 
subspecies is unclear and may reflect true differences as pigtailed macaques contain pDC 
numbers closer to those reported for cynomolgus macaques (54).  
 
In conclusion, this study further defined the phenotypic profile of rhesus macaque DC in blood 
and development of a rapid assay for their enumeration.  Rhesus mDC were phenotypically 
heterogenous but all expressed CD16, a marker traditionally associated with rhesus NK cells and 
a minor proportion of monocytes.  The ability to more accurately identify DC and other cells in 
blood coupled with a rapid assay for their enumeration will greatly enhance the elucidation of 
their role in both health and disease. 
 
Our results have significant implications for the study of DC in the rhesus macaque and highlight 
some key similarities and differences between human and rhesus DC subsets. Rhesus blood 
CD123+ pDC lacked expression of CD11b, CD56 and CD16, as in the human (25). In contrast, 
rhesus blood CD11c+ mDC were uniformly CD11b+ CD16+ CD56lo CD33– CD1c–, a phenotype 
that is quite distinct from human mDC (25). These findings clearly show that inclusion of 
antibodies to CD11b, CD16 and/or CD56 in the lineage cocktail will result in inadvertent 
exclusion of mDC from the lineage– MHC class II+ gate when analyzing rhesus blood. Moreover, 
given that rhesus mDC expressed CD16 at intensities equivalent to NK cells when stained with 
the 3G8 clone, in vivo delivery of this antibody designed to deplete NK cells would likely also 
deplete mDC (141). The lack of CD1c staining on mDC defines an apparent phenotypic 
difference between rhesus and cynomolgus macaques, where CD1c has been used as an 
alternative marker to identify blood mDC (49). We found no evidence for the existence of 
 35 
subsets of mDC in rhesus macaque blood, in contrast to mDC in humans (25). Our antibody 
panel was limited by the fact that antibodies to BDCA-2 and BDCA-3, which have been used to 
define discrete mDC subsets in human blood (25, 138), are not cross-reactive in the rhesus 
macaque (17). It is therefore possible that subsets of mDC do exist in rhesus macaque blood but 
cannot be identified based on available reagents.     
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4.0  CHAPTER TWO. PARALLEL LOSS OF MYELOID AND PLASMACYTOID 
DENDRITIC CELLS FROM BLOOD AND LYMPHOID TISSUES IN SIMIAN AIDS 
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4.2 ABSTRACT 
 
Myeloid (mDC) and plasmacytoid dendritic cells (pDC) are lost from the blood of HIV-infected 
individuals, associated with progressive disease. It has been proposed that DC loss is due to 
increased recruitment to lymph nodes, although this has not been directly tested.  Similar to HIV-
infected humans, we found that lineage-negative (Lin–) HLA-DR+CD11c+CD123– mDC and Lin–
HLA-DR+CD11c–CD123+ pDC were lost from the blood of SIV-infected rhesus macaques with 
AIDS.  In peripheral lymph nodes of SIV-naïve monkeys, the majority of mDC were mature 
cells derived from skin, expressing high levels of HLA-DR, CD83, costimulatory molecules, and 
the Langerhans cell marker CD1a, whereas pDC expressed low levels of HLA-DR and CD40 
and lacked costimulatory molecules, similar to pDC in blood.  Surprisingly, both DC subsets 
were depleted from peripheral and mesenteric lymph nodes and spleen in monkeys with AIDS, 
although the activation status of the remaining DC subsets was similar to DC in health.  In 
peripheral and mesenteric lymph nodes from animals with AIDS, there was an accumulation of 
Lin–HLA-DRmodCD11c–CD123– cells that resembled monocytoid cells, but failed to acquire a 
DC phenotype upon culture, suggesting they were not DC precursors.  mDC and pDC from 
lymphoid tissues of monkeys with AIDS were prone to spontaneous death in culture, indicating 
that apoptosis may be a mechanism for their loss in disease.  These findings demonstrate that DC 
are lost from, rather than recruited to lymphoid tissue in advanced SIV infection, suggesting 
systemic DC depletion plays a direct role in the pathophysiology of AIDS.   
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4.3 INTRODUCTION 
Dendritic cells (DC) are a heterogeneous population of APC essential in bridging the innate and 
adaptive immune responses (16).  The two major DC subsets in humans are CD11c+ 
conventional or myeloid DC (mDC) and CD123+ plasmacytoid DC (pDC) (24, 64).  Although 
mDC and pDC circulate as immature cells in blood, a major stage of their lifecycle takes place in 
lymphoid organs.  mDC populate peripheral tissues as immature cells and migrate to lymph 
nodes through afferent lymphatics where they constitute the only mature DC population and 
stimulate antigen-specific T cells (16, 142, 143).  In contrast, pDC migrate directly from blood to 
lymph nodes across high endothelial venules, residing in significant numbers and exhibiting 
increased recruitment to inflamed lymph nodes where they produce type I IFN and contribute to 
virus-specific T cell responses (62, 63, 80, 144). 
 
Numerous studies have demonstrated that both mDC and pDC are decreased in blood during 
HIV infection (38, 39, 41, 43, 46, 87) with decline being inversely correlated with viral load and 
associated with reduced CD4+ T cell numbers (41, 43).  Recently, pDC were shown to undergo 
phenotypic and functional activation following exposure to HIV-1 in vitro, inducing the 
bystander maturation of mDC (50).  It has been hypothesized that HIV-induced maturation of 
both DC subsets may lead to increased DC migration to lymph nodes, partly explaining their 
disappearance from blood as infection progresses (38, 50).  There are a lack of data regarding 
changes in pDC number or phenotype within lymphoid tissue during HIV infection, and few 
studies defining alteration to mDC.  In situ analysis of peripheral lymph node sections indicated 
that an accumulation of DC-SIGN+ and CD40+ DC occurred during acute HIV infection (51).  
However, in patients with chronic HIV infection, the proportion of DC in the spleen was the 
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same as uninfected controls, suggesting DC may not be recruited to lymphoid tissues in this later 
phase of infection (145).  The current lack of a comparative analysis of mDC and pDC subsets in 
blood and lymphoid tissues leaves the question regarding the ultimate fate of DC during HIV 
infection unanswered.   
 
Experimental infection of rhesus macaques with pathogenic SIV provides a valuable model to 
study the relationship between circulating and lymphoid-resident DC, with typical mDC and 
pDC identified in healthy monkeys (114, 146, 147).  Although reports on the effects of SIV 
infection on circulating DC subsets have been conflicting (114, 146), there is evidence to suggest 
that SIV infection of macaques alters the status of DC in lymph nodes (52, 148).  In the present 
study we defined mDC and pDC in lymphoid tissues and asked whether DC recruitment to 
lymphoid tissues during advanced SIV infection explains the loss of circulating DC in blood. 
4.4 MATERIALS AND METHODS 
4.4.1 Animals and viral infection 
Adult, Indian rhesus macaques (Macaca mulatta) of both sexes were used.  Seven animals were 
infected intrarectally with a characterized stock of the SIV/DeltaB670 primary isolate (149) and 
allowed to progress to AIDS as defined by CD4+ T cell loss, increasing virus loads, 
lymphadenopathy, >20% weight loss, and/or opportunistic infections.  Average time post-SIV 
infection was 50 weeks and the average time to AIDS following SIV/DeltaB670 infection is 11 
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months (150).  Eight animals were used as SIV-naïve controls.  All experiments were performed 
using protocols approved by institutional regulatory committees. 
4.4.2 Cell isolation and flow cytometry 
PBMC were isolated from heparinized blood by Ficoll gradient centrifugation.  Single-cell 
suspensions of axillary and mesenteric lymph nodes and spleen were generated as described 
(151).  For flow cytometric analysis mAb were purchased from BD Pharmingen or BD 
Immunocytometry Systems unless otherwise noted.  Fresh or frozen PBMC, spleen and lymph 
node cell suspensions were blocked with FcR-Blocking Reagent (Miltenyi Biotec) for 15 min at 
4°C before staining, except when analyzing CD16 expression.  Simultaneous identification of 
mDC and pDC in PBMC and spleen was performed using a lineage (Lin) cocktail of FITC-
conjugated mAb against CD3 (SP-34), CD14 (M5E2) and CD20 (2H7), with HLA-DR-
CyChrome (G46-6), CD123-PE (7G3), and CD11c-APC (S-HCL-3).  Expression of 
costimulatory molecules and other receptors on CD11c+ mDC in PBMC and spleen was 
performed by staining with Lin-FITC, HLA-DR-CyChrome, CD11c-APC, and PE-conjugated 
CD80 (L307.4), CD86 (FUN-1), CD83 (HB15a; Coulter-Immunotech), CD40 (EA-5; Ancell) 
and CD1a (SK9).  The immunophenotype of CD123+ pDC in PBMC and spleen was determined 
using Lin-APC, HLA-DR-CyChrome, CD123-PE and FITC-conjugated CD80, CD83, CD86, 
and CD40.  Three-color analysis of axillary and mesenteric lymph node single-cell suspensions 
was performed using Lin-FITC and HLA-DR-CyChrome in addition to PE-conjugated CD11c, 
CD123, CD14 (MФP9), CD20 (L27), CD80, CD83, CD86, CD40, or CD1a.  Analysis of 
purified cells was performed using previously mentioned mAb in addition to CD11b (D12), p55 
(55K-2; DakoCytomation), CD16 (3G8), and CD45 (D058-1283).  Multicolor flow cytometric 
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analysis of DC activation was performed using Lin-PE-Cy7, HLA-DR-PerCP, CD123-PE, 
CD11c-APC, FITC-conjugated costimulatory markers and CD20-Pacific Blue (2H7; 
eBioscience) plus a violet fluorescent LIVE/DEAD fixable dead cell stain (Invitrogen).  Viability 
of cultured lymph node cell suspensions was performed in a similar manner using Lin-PE-Cy7, 
HLA-DR-PerCP, CD123-PE, CD11c-APC and the LIVE/DEAD stain.  Isotype-matched control 
mAb were included in all experiments.  After staining, cells were fixed with 2% 
paraformaldehyde and 500,000 to one million events acquired using a FACSCalibur or BD 
LSRII flow cytometer and analyzed with CellQuest Pro (BD Immunocytometry Systems)   or 
BD FACSDiva software (BD Bioscience), respectively.  Absolute DC numbers in blood were 
calculated by multiplying the percentage of Lin–HLA-DR+CD11c+ or Lin–HLA-DR+CD123+ 
cells in PBMC by the number of mononuclear cells/µl blood as determined by complete blood 
cell counts.  Determination of absolute DC numbers in lymph node was calculated by 
multiplying the percentage of specific cell populations by the total lymph node cell count per 
gram of tissue. 
4.4.3 Immunofluorescence and light microscopy 
For immunofluorescence, lymph nodes were prepared as described (152) and sections incubated 
with 5 µg/ml purified mouse anti-human CD83, CD123, CD1a, or isotype-matched control Ab 
for 2 h followed by goat anti-mouse IgG conjugated to Alexa 488 (Molecular Probes) for 2 h.  
Nuclei were labeled with Hoescht 33342 (Sigma) and slides imaged using an Olympus Provis 
epifluorescence microscope (Melville, NY).  For light microscopy, purified Lin–HLA-
DR+CD123– cells were spun onto glass slides using a Shandon cytocentrifuge (Shandon) and 
stained with the Hema 3 stain set (Fisher Scientific).   
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4.4.4 Cell purification and culture   
Purification of Lin–HLA-DR+CD123– lymph node cells was performed by depletion of CD3-, 
CD14-, and CD20-positive cells using magnetic microbeads (Miltenyi Biotec) according to the 
manufacturer’s instructions.  The depleted fraction was then labeled with anti-CD123-PE 
followed by anti-PE microbeads to remove CD123+ pDC.  The purity of the remaining cell 
population assessed by flow cytometry was >90%.  Purified cells were cultured at 1 x 106/mL in 
medium alone or with 1000 U/mL recombinant human (rh) GM-CSF and 1000 U/mL rhIL-4 
(both from Schering-Plough), 20 ng/mL rhIL-3 (R&D Systems), or 1.0 μg/mL soluble human 
trimeric CD40L (Immunex) for 24 h.  For cell viability experiments, single-cell suspensions of 
peripheral lymph node or spleen were depleted of CD20-positive cells using magnetic 
microbeads (Miltenyi Biotec) according to the manufacturer’s instructions and cultured at 1 x 
106/mL for 24 h in medium alone or with 20 ng/mL rhIL-3.   
4.4.5 Statistical analysis 
Differences between SIV-naïve monkeys and animals with AIDS were determined by 
comparison of means using the nonparametric Mann-Whitney U test.  Two-tailed P values less 
than 0.05 were considered significant at an alpha level of 0.05.  Differences between DC 
viability before and after culture were determined by comparison of means using the paired t test.  
One-tailed P values less than 0.05 were considered significant.  All data are presented as the 
mean ± SEM.   
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4.5 RESULTS 
4.5.1 Blood mDC and pDC are lost in monkeys with AIDS 
To clarify whether DC are reduced in the blood of monkeys with AIDS, the two major DC 
subsets were identified in PBMC as Lin–HLA-DR+CD11c+CD123– mDC or Lin– HLA-
DR+CD11c–CD123+ pDC (Fig. 6A).  Previous studies of macaque DC included CD11b and 
CD16 as lineage markers to stain NK cells (19, 146).  However NK cells are found within the 
Lin– HLA-DR– fraction of PBMC from rhesus macaques (153) thus eliminating the need to 
include NK cell markers for exclusion from the Lin–HLA-DR+ fraction of PBMC.  In addition, 
preliminary experiments demonstrated that mDC expressed CD16 as well as low levels of  
CD11b (data not shown), consistent with the findings of others (114).  Hence we did not include 
mAb to CD16 and CD11b in our analyses.  In healthy monkeys and animals with AIDS, mDC 
predominated in the Lin–HLA-DR+ fraction, while pDC comprised only a minor proportion of 
cells (Fig. 6A), consistent with previous findings (146, 147).  In addition, mDC and pDC 
expressed similar and relatively low levels of HLA-DR in SIV-naïve monkeys (Fig. 6A) and 
animals with AIDS (data not shown).  When the absolute number of cells was calculated, mDC 
and pDC were significantly reduced in the blood of animals with AIDS while the number of Lin– 
HLA-DR+CD11c–CD123– cells was relatively unchanged compared to SIV-naïve monkeys (Fig. 
6B).  The phenotype of mDC from SIV-naïve monkeys and animals with AIDS was similar, 
expressing low levels of CD86 and lacking CD80, CD83, and CD40 (Fig. 6C).  pDC from both 
groups were also phenotypically similar, except for a slight increase of CD40 expression in 
monkeys with AIDS (Fig. 6D).  These data indicate that circulating mDC and pDC in rhesus 
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macaques are immature cells that are significantly decreased during simian AIDS, consistent 
with the findings in HIV-infected individuals (38, 39, 41, 43, 87). 
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Figure 6. mDC and pDC are decreased in blood during simian AIDS 
A, PBMC were gated based on forward/side scatter characteristics and DC identified within the lineage (CD3, 
CD14, CD20)-negative (Lin–) HLA-DR+ fraction (R1) from SIV-naïve animals and monkeys with AIDS.  One 
representative experiment of eight is shown to demonstrate the gating strategy used to identify DC subsets.  
Numbers represent the percentage of cells within R1.  B, Absolute number of cells/µl of blood for cell populations 
within the Lin–HLA-DR+ fraction (R1) are shown.  Data represent the mean ± SEM for naïve monkeys (n=6) and 
animals with AIDS (n=4).  *P<0.02.  Immunophenotype of (C) CD11c+ mDC and (D) CD123+ pDC in SIV-naïve 
animals and macaques with AIDS.  One representative experiment of four is shown for both groups.  Vertical bars 
denote the level of isotype control Ab staining.  
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4.5.2 High proportion of pDC and mature, epidermis-derived mDC in superficial lymph 
node of healthy macaques 
In order to determine the effects of SIV infection on mDC and pDC in lymph nodes we first 
characterized DC subsets from normal, SIV-naïve macaques in a manner comparative to blood.  
Initially, a population of cells not observed in blood and expressing high levels of HLA-DR was 
identified which appeared to express lineage markers, similar to recent studies using human 
lymph nodes (32).  However, staining with different mAb clones than those used in the lineage 
cocktail revealed a lack of CD14 and CD20 expression, indicating a high level of 
autofluorescence rather than lineage marker expression (Fig. 7A).  Therefore, in all future 
analyses, this unique population was included in the gate defining the Lin–HLA-DR+ fraction of 
the lymph node.  In normal monkeys, the Lin–HLA-DR+ fraction represented only 2% of total 
lymph node cells and could be subdivided into three populations based on HLA-DR expression; 
HLA-DRhi, HLA-DRmod, and HLA-DRlo (Fig. 7B).  The majority of CD11c+ mDC were HLA-
DRhi with a minor proportion being HLA-DRmod, whereas CD123+ pDC were exclusively HLA-
DRlo (Fig. 7B), demonstrating that mDC and pDC in lymph nodes could be differentiated based 
on HLA-DR expression, similar to recent findings in humans (32).  Lin–HLA-DRhi mDC 
uniformly expressed moderate to high levels of CD80, CD83, CD86, and CD40, a phenotype 
characteristic of mature DC (Fig. 7C).  In contrast, Lin–HLA-DRlo pDC lacked CD80, CD83, and 
CD86, and expressed low levels of CD40, consistent with immature cells (Fig. 7C).  Lastly, the 
Lin–HLA-DRmod population displayed an intermediate phenotype, with the majority of cells 
expressing CD80, CD86, and CD40 but low to undetectable levels of CD83 (Fig. 7C).   
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In the steady state, the majority of lymphoid organ DC with a mature phenotype are those that 
migrate from epithelial surfaces (143).  Mature DC in peripheral lymph nodes originate from 
either dermal DC or epidermal LC, the latter identified by strong expression of CD1a (154).  
Notably, Lin–HLA-DRhi mDC, but not other DC subsets in the superficial lymph node, expressed 
CD1a (Fig. 7C).  In contrast, CD1a was not expressed by cells within the Lin–HLA-DR+ fraction 
of blood (Fig. 7D), consistent with findings in humans (25).  Collectively, these findings 
demonstrate that in superficial lymph nodes from SIV-naïve monkeys, pDC are phenotypically 
immature and likely derive from blood, whereas the majority of mDC are mature, epidermis-
derived cells, consistent with studies of lymph node DC in mice and humans (31, 62-64). 
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Figure 7. pDC and epidermal-derived mature mDC differentially express HLA-DR in superficial 
lymph node from normal monkeys 
 
A-C, Axillary lymph node cell suspensions from SIV-naïve monkeys were analyzed by flow cytometry. Total lymph 
node cells were gated based on forward/side scatter characteristics and DC identified within the Lin–HLA-DR+ 
fraction (R1). A, Staining of cells expressing high levels of HLA-DR with isotype control Ab or Ab to CD14 and 
CD20.  B, Representative dot plot demonstrating the gating strategy used to define the Lin–HLA-DR+ fraction (R1) 
of lymph node and the three populations of HLA-DR-expressing cells within R1.  Numbers represent the percentage 
of cells within R1 indicated by gates or brackets.  C, Expression of maturation and costimulatory molecules and 
CD1a by Lin–HLA-DR+ cells.  D, Lack of CD1a expression by the Lin–HLA-DR+ fraction of PBMC.  Data shown 
are representative of four (A,C,D) and 16 (B) experiments. 
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4.5.3 Major loss of pDC and epidermis-derived mature mDC from superficial lymph 
nodes in monkeys with AIDS 
To determine the impact of SIV on DC populations in lymphoid tissue, we analyzed superficial 
lymph nodes from animals with AIDS.  A major loss in the proportion of the Lin–HLA-DRhi 
cells was noted, corresponding to a reduction of CD11c+ mDC.  In addition, there was a dramatic 
decrease in the proportion of CD123+ pDC in monkeys with AIDS compared to SIV-naïve 
animals (Fig. 8, A and C).  Although reduced, the remaining mDC exhibited a mature phenotype 
expressing CD80, CD83, CD86, CD40, and CD1a, while pDC only expressed CD40 (Fig. 8B), 
similar to SIV-naive monkeys.  Despite the reduction of pDC and mature mDC,  the proportion 
of lymph node cells within the Lin–HLA-DR+ fraction increased in animals with AIDS, related to 
an increase of HLA-DRmod-expressing cells (Fig. 8, A and C).  This population was not 
accounted for by either mDC or pDC and displayed a less defined phenotype, expressing CD40, 
low CD80, heterogeneous CD86, but not CD83 or CD1a (Fig. 8, A and B).  To determine 
whether decreases in the proportion of mDC and pDC translated to an absolute loss of cells, cell 
numbers were standardized against tissue mass.  The total number/gram of Lin–HLA-DR+ cells 
did not change between naïve animals and monkeys with AIDS, but the absolute number of Lin–
HLA-DRhi cells was significantly decreased while Lin–HLA-DRmod cell numbers increased (Fig. 
8D).  When the Lin–HLA-DR+ fraction was analyzed for expression of CD11c and CD123, the 
absolute numbers of both pDC and mature mDC were significantly decreased compared to SIV-
naïve animals (Fig. 8D), consistent with the observed changes in cell proportions.   
 
In general, lymph nodes from animals with AIDS contained approximately 50% fewer cells per 
gram of tissue than SIV-naïve monkeys likely due to tissue fibrosis and lymphadenopathy (data 
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not shown).  Hence, assessment of DC subsets as absolute number of cells/gm of tissue may be 
influenced by the stage of disease.  Therefore, in order to confirm the reduction in both 
percentage and absolute number of DC in lymph nodes during AIDS, immunofluorescent 
analysis was performed on lymph node sections.  CD83 and CD1a mAb were used to identify 
mature mDC, as staining was superior to that of the CD11c mAb (data not shown).  In naïve 
animals, both CD83bright and CD1a+ cells resided in lymph node paracortical regions outside of 
follicles (Fig. 8, E and G).  Consistent with our observations by flow cytometry, very few 
CD83bright or CD1a+ cells were found in lymph nodes from animals with AIDS (Fig. 8, F and H).  
Staining for CD123 demonstrated that pDC also resided in paracortical areas of lymph node from 
naïve animals and confirmed their depletion in animals with AIDS (Fig. 8, I and J). 
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 Figure 8. pDC and mature mDC are depleted in superficial lymph node from monkeys with AIDS 
A-B, Axillary lymph node cells from monkeys with AIDS were analyzed by flow cytometry and DC identified 
within the Lin–HLA-DR+ fraction (R1).  A, Representative plot illustrating the gating strategy used to define R1 and 
the three HLA-DR-expressing populations within R1.  Numbers represent the percentage of cells within R1 denoted 
by gates or brackets.  B, Flow cytometric analysis of maturation and costimulatory molecule expression by cells 
within R1.  C, Percentage and (D) absolute number of cells/gram of tissue within the Lin–HLA-DR+ fraction of 
lymph node from SIV-naïve monkeys (n=8) and animals with AIDS (n=7).  Data represent the mean ± SEM. 
*P<0.05, **P<0.01, ***P<0.001.  (E-J)  Immunofluorescent analysis of axillary lymph node sections from both 
groups of monkeys for expression of CD83 (E,F), CD1a (G,H), and CD123 (I,J).  Isotype control Ab is inset in (E).  
Positive staining for the indicated markers is in green and cell nuclei stained with Hoescht dye in blue. F = follicle.  
Arrows in (I) indicate individual cells expressing CD123.  Images are representative of three animals per group.  
Original magnification 200X.  
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To further analyze the phenotype of DC subsets in peripheral lymph nodes we used a 6-color 
flow cytometry panel.  We gated out non-viable and CD20+ cells and analyzed pDC and mDC 
simultaneously (Fig. 9A).  In SIV-naïve animals, the majority of Lin–HLA-DR+CD11c+ mDC 
expressed CD80, CD83, CD86, and CD40 (Fig. 9B) consistent with our previous results.  
However in monkeys with AIDS, the remaining mDC lacked CD83, but retained expression of 
CD40 and low levels of CD80 and CD86 (Fig. 9B).  This likely reflects the preferential loss of 
mature, skin-derived mDC from lymph nodes with the remaining mDC being primarily the 
relatively immature HLA-DRmod cells (Fig. 8A).  pDC from SIV-naïve animals and monkeys 
with AIDS were phenotypically similar and expressed similar levels of CD40 (Fig. 9B), 
suggesting that the remaining pDC did not have an altered state of activation in peripheral lymph 
nodes.   
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 Figure 9. Multicolor analysis of DC subsets in peripheral lymph nodes. 
A-B, Lymph node single-cell suspensions were labeled with the indicated mAb followed by staining with the 
LIVE/DEAD cell viability dye (L/D).  A, Representative plots from an SIV-naïve animal demonstrating the gating 
strategy used to define DC subsets.  Viable, CD20-negative cells were gated against side scatter (SSC) (R1) 
followed by an additional forward scatter (FSC)/SSC gate (R2).  DC subsets were simultaneously identified within 
the Lin–HLA-DR+ fraction (R3) and analyzed for maturation and costimulatory molecule expression in (B).  B, 
Costimulatory molecule expression (heavy line) versus isotype control staining (thin line) in mDC (top panels) and 
pDC (bottom panels) from SIV-naïve monkeys and animals with AIDS.  All data are representative of four SIV-
naïve animals and four monkeys with AIDS.  
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4.5.4 mDC and pDC are decreased in mesenteric lymph node and spleen during AIDS 
To determine if the decreases in pDC and mature mDC in superficial lymph nodes during AIDS 
reflected alterations in other lymphoid compartments, we extended our analysis to the mesenteric 
lymph nodes.  As in superficial lymph nodes, three populations of HLA-DR-expressing cells 
could be distinguished within the Lin–HLA-DR+ fraction of mesenteric lymph node from SIV-
naïve animals, with the majority of mDC being HLA-DRhi and pDC being HLA-DRlo (Fig. 10A).  
Furthermore, the pattern of maturation and costimulatory molecule expression of DC closely 
resembled that of superficial lymph nodes from both groups, with HLA-DRhi mDC having a 
mature phenotype and HLA-DRlo pDC having an immature phenotype (Fig. 10B).  Notably, Lin–
HLA-DRhi CD11c+ mature mDC from both groups lacked expression of CD1a (Fig. 10B), 
consistent with findings in human lymphoid tissues draining mucosal epithelium (31, 155).  
Overall, the proportion of pDC and mature mDC decreased whereas the proportion of Lin–HLA-
DRmod cells increased in monkeys with AIDS (Fig. 10, A and C), similar to superficial lymph 
nodes. 
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 Figure 10. mDC and pDC are decreased in mesenteric lymph nodes from animals with AIDS 
A, Mesenteric lymph node cells from SIV-naïve monkeys and animals with AIDS were analyzed by flow cytometry 
and DC identified within the Lin–HLA-DR+ fraction (R1).  A representative dot plot demonstrating the gating 
strategy used to define R1 and the three HLA-DR-expressing populations is shown.  Numbers represent the 
percentage of cells within R1 indicated by gates or brackets from one representative experiment of 4 (naïve) and 5 
(AIDS) animals.  B, Dot plots demonstrating the expression pattern of maturation and costimulatory molecules and 
CD1a in an SIV-naïve monkey and an animal with AIDS.  mDC and pDC denote the location of these cells within 
the Lin–HLA-DR+ fraction.  Representative of four animals per group.  C, Percentage of cells within R1.  Data 
represent the mean ± SEM for naïve animals (n=4) and monkeys with AIDS (n=4). *P<0.04, **P<0.02 
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Finally, we assessed whether DC may have accumulated in the spleen, which anatomically is 
accessible only via the blood.  The spleen lacked the HLA-DRhi population of cells 
corresponding to epithelium-derived mature mDC in lymph nodes (Fig. 11A), consistent with 
previous finding in mice (143, 156).  Both mDC and pDC in spleen were significantly reduced in 
monkeys with AIDS compared to normal animals (Fig. 11B).  The phenotype of splenic DC in 
both groups was similar, except for a marginal increase of CD40 expression in animals with 
AIDS (Fig. 11, C and D). 
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 Figure 11. mDC and pDC are depleted in spleen from monkeys with AIDS. 
A, Single-cell suspensions of spleen from SIV-naïve monkeys and animals with AIDS were labeled with the 
indicated mAb and DC identified within the Lin–HLA-DR+ fraction (R1).  B, Percentages of cells within R1 from 
SIV-naïve animals (n=5) and animals with AIDS (n=4).  Data represent the mean ± SEM.  *P<0.04, **P<0.02.  C-D 
Dot plots showing the expression of maturation and costimulatory molecules by (C) mDC (Lin–HLA-DR+CD11c+) 
and (D) pDC (Lin–HLA-DR+CD123+) in an SIV-naïve animal and an animal with AIDS.  Vertical bars denote the 
level of isotype control Ab staining.  All data are representative of five SIV-naïve animals and four monkeys with 
AIDS. 
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4.5.5 Lin-HLA-DRmod cells that accumulate in lymph nodes from animals with AIDS do 
not acquire a DC phenotype following culture      
In a previous study, we showed that culture of Lin–HLA-DR+CD11c–CD123– cells from blood 
resulted in CD11c expression by a major fraction of cells indicative of DC precursors (147), and 
it is possible that the population of Lin–HLA-DRmodCD11c–CD123– cells in lymph nodes during 
AIDS similarly represent DC precursors.    Light microscopic analysis of purified Lin–HLA-
DRmodCD123– cells revealed a dull gray-blue cytoplasm and convoluted nuclei, resembling 
monocytoid cells (Fig. 12A).  Flow cytometric analysis of purified Lin–HLA-DRmodCD123– cells 
prior to culture demonstrated CD45 and CD40 expression by all cells while approximately 50% 
expressed the costimulatory molecule CD86 (Fig. 12A and B).  The Lin–HLA-DRmod population 
lacked expression of the DC markers, CD11c and CD123, consistent with the analysis of total 
lymph node cells, as well as the pan DC marker p55 (Fig. 12B).  In addition, freshly isolated 
cells did not express CD11b or CD16, suggesting they are not NK cells (Fig. 12B).  To test the 
hypothesis that Lin–HLA-DRmod CD11c– CD123– cells may represent DC precursors, purified 
cells were cultured in growth factors known to result in DC differentiation.  Culture with GM-
CSF and IL-4, IL-3, or CD40L did not result in CD11c or CD123 expression (Fig. 12C), 
indicating the Lin–HLA-DRmod cells were unlikely to be DC precursors.  In addition, 
approximately 50% of the cells were non-viable after 24 h by trypan blue exclusion (data not 
shown), indicating growth factors had no impact on cell survival.  Culture also did not result in 
CD14 or CD20 expression (Fig. 12C), ruling out the possibility that this unique population 
differentiated to a monocyte/macrophage or B cell.  Nevertheless, under all conditions the 
majority of cells upregulated CD86 expression demonstrating an effect of culture (Fig. 12C). 
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 Figure 12. Lin–HLA-DRmod cells from monkeys with AIDS are not DC precursors. 
A, Lymph node single-cell suspensions were depleted of Lin+ and CD123+ cells and the depleted fraction analyzed 
by flow cytometry or stained with Hema 3 and examined by light microscopy.  Original magnification 1000X.  B, 
Purified cells from (A) were analyzed with a panel of mAb by flow cytometry.  C, Purified cells were analyzed by 
flow cytometry following 24 h culture in the indicated conditions.  Data are representative of three animals 
analyzed. 
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4.5.6 Spontaneous death of mDC and pDC from lymphoid tissues of monkeys with AIDS 
To begin to address the mechanism of DC depletion, we sought to determine whether DC in 
animals with AIDS may be susceptible to spontaneous cell death in culture.  To increase the 
frequency of DC, we depleted lymph node or spleen cell suspensions of CD20+ B cells, and to 
provide a survival factor for pDC we included IL-3 (64).  Before and 24 h after culture, we used 
the LIVE/DEAD viability dye to identify post apoptotic or necrotic cells within the mDC or pDC 
fraction (Fig. 13A).  We first studied mDC and pDC from spleen, which are phenotypically 
similar to their respective DC subsets in blood.  At the onset of culture, mDC and pDC from both 
groups contained a similar high percentage of viable cells (Fig. 13B).  However, there was a 
significant decrease in the viability of pDC from animals with AIDS, but not from SIV-naïve 
monkeys (Fig. 13B).  In addition, mDC viability significantly decreased in animals with AIDS 
following culture, whereas mDC from naïve monkeys showed a minimal loss of viability (Fig. 
13B).  Similarly, mDC from the peripheral lymph node of animals with AIDS demonstrated a 
significant loss of viability following culture as compared to mDC from SIV-naïve animals (Fig. 
13B).  Together, these data indicate that both mDC and pDC from animals with AIDS are more 
prone to spontaneous cell death. 
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 Figure 13. DC from animals with AIDS undergo increased cell death in culture. 
A, CD20-depleted single-cell suspensions of peripheral lymph nodes or spleen were analyzed before and 24 h after 
culture by flow cytometry.  Representative dot plots from an SIV-naïve peripheral lymph node sample illustrate the 
gating strategy used to identify mDC and pDC.  The R2 gate used for spleen was similar to Fig. 6.  Histograms 
represent the LIVE/DEAD staining pattern of peripheral lymph node mDC and splenic pDC from an animal with 
AIDS.  Brackets denote the gate used to quantitate viable cells before and after culture.  B, Percentage of viable cells 
for pDC and mDC from SIV-naïve monkeys (n=4) and animals with AIDS (n=4) before and after culture.  Data 
represent the mean ± SEM.  *P<0.02, **P<0.01.  
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4.6 DISCUSSION  
Our findings contribute considerable insight to the current understanding of DC dynamics during 
HIV infection and point to a more direct role of systemic DC loss in the pathophysiology of 
immunodeficiency.  We demonstrate that the loss of circulating DC in progressive SIV infection 
is not due to recruitment to lymph nodes but rather is a component of the generalized loss of both 
DC subsets from blood and lymphoid tissues. The notion that DC recruitment to lymph nodes 
may in part explain their disappearance from blood arises from the observed phenotypic 
activation of DC subsets following in vitro or in vivo exposure to HIV (41, 50, 157).  However, 
clear differences in the phenotypic activation of mDC and pDC was not observed by us or others 
in SIV-infected macaques (146).  Increasing evidence suggests that the interaction between mDC 
and pDC is important in the induction of virus-specific immune responses in lymph node (80, 
144) and stimulation of HIV-specific CD4+ T cell responses (50).  Therefore, the loss of both DC 
subsets from lymphoid tissues in advanced infection would clearly reduce the capacity to 
respond to HIV or opportunistic infections and could therefore contribute to the onset of 
immunodeficiency.  In contrast, early in HIV infection, DC recruitment to lymph nodes could 
facilitate viral spread and infection of susceptible T cells (158).  Indeed, DC accumulate in the 
lymph node paracortex during acute infection with either SIV or HIV (51, 52), coincident with 
massive depletion of memory T cells (7).   
 
The mechanism of DC depletion from blood and lymphoid tissue during AIDS is likely to be 
complex. Our findings indicate that mDC and pDC undergo spontaneous cell death during 
culture, supporting the hypothesis that loss of DC may be due to cell death (159, 160).  Notably, 
the amine reactive viability dye used in this study identifies not only necrotic but also late or post 
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apoptotic cells (161), and  preliminary experiments have identified viable DC in lymph nodes of 
monkeys with AIDS which are annexin V-positive (data not shown) suggesting DC may be 
undergoing apoptosis.  pDC and mDC in blood do harbor virus, suggesting direct infection may 
contribute to loss of cells from the circulation (40), however exposure of pDC to HIV in vitro 
promotes pDC survival, not death (50, 97).  In addition, the frequency of infected pDC and mDC 
in tissues appears too low to support a major role of infection in depletion of tissue-resident DC 
(52, 96, 162, 163).  It is possible that apoptosis of DC in HIV and SIV infection is mediated by 
binding of TNF family ligands to cognate death receptors involving FasL binding to Fas or TNF-
related apoptosis-inducing ligand (TRAIL)/DR5 interactions.  Fas/FasL  and TRAIL/DR5 have 
been shown to play a role in the apoptosis of T cells in HIV infection (122-124, 164) and both 
TRAIL- and Fas-mediated pathways have been implicated in DC apoptosis during measles virus 
infection (127, 165).  In addition, we have previously shown that a significant factor in the loss 
of DC from lymph node may be failed trafficking of DC from epithelial surfaces (52).  
Consistent with this finding, the predominant mDC population lost from lymph nodes of 
monkeys with AIDS was the mature, skin-derived DC, while the relatively immature HLA-
DRmod mDC subset was decreased to a lesser degree.  Although HIV and SIV can infect 
Langerhans cells (166, 167), evidence for significant infection of Langerhans cells during 
progressive infection is lacking.  Moreover, Langerhans cells migrate with normal efficiency 
from the skin in SIV-infected monkeys at the time of peak virus load indicating that failed 
Langerhans cell migration is not simply a function of high virus burden (52).  Ultimately, 
calculating the precise viral burden in mDC and pDC as well as investigating apoptotic pathways 
will be required to determine mechanisms of DC loss during SIV and HIV infection.   
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 Despite the reduction of pDC and mature mDC in lymph nodes, we observed an increase in a 
population of Lin–HLA-DRmodCD11c– CD123– cells within the Lin–HLA-DR+ fraction of lymph 
nodes from animals with AIDS resembling monocytoid cells and expressing CD40 and CD86 
suggesting a role as an APC.  Recently, an increased frequency of circulating blood DC lacking 
CD11c and CD123 expression that elicited poor T-cell proliferation and IFN-γ secretion was 
identified in cancer patients (128).    Moreover, lymph nodes of HIV-infected subjects were 
found to contain an abundance of semimature DC defined as being Lin–CD83+ IL-12–, which 
induced allogeneic T cells to adopt a regulatory T cell phenotype (168).  While there is no 
evidence that the Lin–HLA-DRmod cells in our study represent DC, the phenotype of low CD86 
and lack of CD80 expression are consistent with these cells being regulatory rather than 
immunostimulatory DC. 
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5.0  CHAPTER THREE.  PLASMACYTOID DENDRITIC CELL DEATH AND 
DEPLETION FOLLOWING MASSIVE RECRUITMENT TO LYMPH NODES IN 
ACUTE IMMUNODEFICIENCY VIRUS INFECTION 
5.1 PREFACE 
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5.2 ABSTRACT 
Plasmacytoid dendritic cells (pDC) are lost from the circulation in HIV infection associated with 
disease progression but the mechanism for this loss is not known.  Using precise enumeration 
and approaches to track recently divided cells, we show that the pDC response to intravenous 
SIV inoculation in rhesus macaques is highly dynamic with rapid mobilization into blood 
followed by a 10 to 20-fold increase in pDC recruitment to lymph nodes.  However, pDC were 
depleted from lymph nodes faster than they were replenished.  Lymph node pDC had increased 
levels of apoptosis and necrosis, were uniformly activated and were infected at frequencies 
similar to CD4+ T cells.  Nevertheless, lymph node pDC had essentially normal responses to 
Toll-like receptor 7 stimulation.  We propose that the rapid recruitment of pDC to inflamed 
lymph nodes in acute immunodeficiency virus infection has a pathologic consequence, bringing 
cells into close contact with virus, virus-infected cells and pro-apoptotic factors leading to pDC 
death. 
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5.3 INTRODUCTION 
Plasmacytoid dendritic cells (pDC) are important in bridging innate and adaptive immune 
responses to pathogens (62, 65, 80).  pDC derive from bone marrow and are recruited into lymph 
nodes in response to inflammation, producing  type I interferons (IFN) and contributing to the 
generation of virus-specific T cell responses (55, 62, 63, 80).  Human immunodeficiency virus-1 
(HIV) infection of humans and simian immunodeficiency virus (SIV) infection of monkeys 
result in pDC loss from blood that is correlated with high viral load and reduced numbers of 
CD4+ T cells (38, 41, 43, 46, 49, 54, 84, 85, 87, 91, 169).  pDC-derived type I IFN limits HIV 
replication in CD4+ T cells (76-78) and frequencies of pDC  are higher in HIV-infected long-
term non-progressors than healthy donors (170), suggesting that diminished pDC numbers likely 
contribute to the lack of  immune control in this disease.  However, the mechanism of pDC loss 
in HIV infection has not been defined. 
 
A central hypothesis accounting for pDC depletion from blood during HIV infection is 
recruitment to inflamed lymphoid tissues (50, 76).  Evidence for pDC recruitment comes from 
the finding that pDC exposed to HIV express the chemokine receptor CCR7 required for homing 
to lymph node paracortex (50), and recent data in rhesus macaques confirm that CCR7 is induced 
on circulating pDC in response to pathogenic SIV infection (171).  Moreover, expression of 
CXCL9 is highly upregulated in lymphoid tissues in acute SIV infection (103, 104), and pDC 
enter lymph nodes in a CXCL9-dependent manner (63).  However, there is also substantial 
evidence to support a role for cell death in pDC loss in HIV infection.  HIV infects pDC both in 
vitro and in vivo and induces cytopathic effects and death following maturation (40, 95-98).  In 
addition, pDC from HIV-infected individuals undergo death by apoptosis and necrosis following 
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interaction and fusion with HIV-infected cells (78).  The relative contribution of recruitment to 
tissues and cell death to pDC loss in HIV infection remains to be determined.  
 
To tease out the different potential mechanisms of pDC loss, we studied kinetics of the pDC 
response during acute infection of rhesus macaques with the pathogenic SIV strain SIVmac251. 
We enumerated pDC in different compartments and used in vivo labeling with the thymidine 
analogue 5-bromo-2’-deoxyuridine (BrdU) together with Ki-67 staining to document 
mobilization and recruitment of recently divided cells that would otherwise be obscured by net 
cell loss.  We find that pDC are lost from blood and peripheral lymph nodes early in SIV 
infection despite massive mobilization and recruitment, associated with pDC activation, infection 
and death in lymph nodes.  These findings demonstrate that pDC recruitment and killing work 
together in the context of the lymph node to bring about pDC depletion in SIV infection. 
 
5.4 MATERIALS AND METHODS 
5.4.1 Animals, virus infection and sample collection 
Six adult female rhesus macaques (Macaca mulatta) were infected by intravenous inoculation 
with 1,000 TCID50 SIVmac251 (kindly provided by Preston Marx, Tulane National Primate 
Research Center) and compared to a cohort of six SIV-naive controls.  Blood samples were 
collected in either EDTA or ACD four to six times prior to infection including day 0 and on days 
3, 6, 10, 11, 12, 13 and 14 post-infection.  BrdU (Sigma) was prepared in Ca2+/Mg2+-free HBSS 
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at 10 mg/ml, filter-sterilized and administered by intravenous injection at 30 mg/kg at 24-hour 
intervals for 4 doses starting on day 10 post-infection.  Parallel BrdU administration was given to 
two SIV-naïve monkeys.  Bone marrow aspirates were obtained at least 30 days prior to and on 
day 12 post-SIV infection from the medullary cavity of the right femur using a Jamshidi bone 
marrow biopsy needle flushed with heparin.  SIV-infected animals were sacrificed on day 14 
post-infection and the two SIV-naive animals receiving BrdU were sacrificed 24 hours after the 
final drug dose.  All animals underwent transcardiac saline perfusion at the time of sacrifice to 
ensure removal of peripheral blood from tissues.  All experiments were performed using 
protocols approved by appropriate institutional regulatory committees. 
5.4.2 Sample processing   
PBMC were isolated by density gradient centrifugation over Ficoll.  Alternatively, blood samples 
were lysed of red blood cells using ACK lysing buffer for isolation of peripheral blood 
leukocytes (PBL).  Lymph node single-cell suspensions were generated and depleted of CD20+ B 
cells as previously described (85).  Bone marrow aspirates were passed over a 70 μm nylon cell 
strainer to remove spicules and diluted 1:1 with PBS prior to erythrocyte lysis and counting 
using trypan blue exclusion.  All blood, lymph node and bone marrow preparations were frozen 
in medium containing 90% FBS and 10% DMSO (Sigma) using a controlled-rate freezer 
(CryoMed) and stored in liquid nitrogen.  Viral RNA levels in plasma were determined by real-
time PCR using an ABI Prism 7900H sequence detection system (Applied Biosystems) using 
reverse-transcribed viral RNA as templates, as described (172).   
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5.4.3 Flow cytometry and enumeration of cells 
All antibodies were purchased from BD Biosciences unless noted otherwise.  For the majority of 
analyses cells were stained with antibodies to Lineage markers [CD3 (clone SP34-2), CD14 
(M5E2), and CD20 (2H7, eBioscience)], CD45 (D058-1283), HLA-DR (G46-6), and CD123 
(7G3) with or without an amine-reactive Live/Dead cell viability dye (Invitrogen) using 
mutually-exclusive fluorochrome conjugates.  In some experiments cells were co-stained with 
antibody to CD95 (DX2) or with 5.0 μg/mL 7-AAD and Annexin V (BD Biosciences). 
Alternatively, labeled cells were fixed and permeabilized with Cytofix/Cytoperm (BD 
Biosciences) and incubated with antibody to Ki-67 (B56).  To detect BrdU incorporation, labeled 
cells were fixed with 4% formaldehyde prior to pretreatment with 10 Kunitz units DNaseI 
(Roche)/106 cells in 0.1% saponin containing 4.2 mM MgCl2 and 10mM NaCl.  Cells were 
washed with saponin and incubated with anti-BrdU-FITC (B44) prepared in the previous 
solution containing 10 Kunitz units DNaseI/106 cells for 45 min at RT.  BrdU positivity was 
determined by staining samples from animals not delivered BrdU.  Absolute numbers of CD45+ 
mononuclear cells and CD4+ T cells in blood were determined by staining 50μL of whole blood 
with antibodies to CD3, CD4 (L200) and CD45 using TruCOUNT tubes (BD Biosciences) as per 
the manufacturer’s recommendations.  For pDC quantification PBL were stained with antibodies 
to define pDC and the absolute number of pDC/μL blood calculated by multiplying the 
percentage of pDC within the CD45+ fraction by the absolute number of CD45+ cells.  A similar 
method was used to calculate mononuclear cells and pDC in bone marrow aspirates.  For 
analysis of intracellular cytokine expression PBMC were stimulated for 5 hours in media alone 
or with 10 μM of the TLR7/8 agonist 3M-007 (3M Pharmaceuticals) in the presence of 10 
μg/mL brefeldin A (Sigma) for the final 3 hours.  Alternatively, CD20-depleted lymph node cells 
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were stimulated for 12 hours with 10 μM 3M-007 agonist in the presence or absence of 10 
μg/mL brefeldin A. Cells were stained with surface-labeling antibodies and fixed and 
permeabilized as above prior to incubation with antibodies to TNF-α (MAb11) and/or IFN- α 
(MMHA-2, PBL Biomedical Laboratories).  Antibody to IFN- α was conjugated to Alexa 647 
using Zenon labeling technology according to the manufacturer’s protocol (Invitrogen).  Flow 
cytometry data was acquired using a BD LSR II or FACS Aria flow cytometer and analyzed with 
BD FACS Diva software (version 5.0.2) and histogram overlays generated using FlowJo version 
7.2.4 (Tree Star, Inc.).  
5.4.4 Cell sorting 
Previously cryopreserved lymph node cell suspensions were thawed in the presence of DNAse, 
strained and then stained with antibodies to Lineage markers, HLA-DR, CD123 and CD11c (S-
HCL-3) along with the Live/Dead viability dye. Between 5,000 and 10,000 viable Lin– HLA-
DR+ CD123+ CD11c– pDC and Lin– HLA-DR+ CD123– CD11c+ mDC were sorted 
simultaneously using a BD FACS Aria flow cytometer, making sure to exclude doublets on the 
basis of forward scatter and side scatter height and width parameters.  For purification of CD4+ T 
cells, lymph node suspensions were stained with antibodies to CD3, CD4 and CD8 (B9.11, 
Immunotech) and 50,000 viable CD3+CD4+CD8– cells sorted as above.  Purified cells were 
deposited into tubes containing lysis buffer for DNA isolation or into tubes containing media 
followed by centrifugation onto slides (Cytospin 3, Shandon).  Slides were fixed and stained 
using a modified Wright-Giemsa stain (Hema 3, Fisher) and images taken using an Olympus 
BX51 light microscope.  
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5.4.5 Quantification of SIV proviral DNA 
Cellular DNA from sorted cells was isolated using DNAeasy blood and tissue kit (Qiagen).  For 
quantitative PCR analysis, a plasmid was first generated by inserting sequences of SIVsmB7 
LTR and SIVmac239 gag in the pUC19 plasmid along with macaque albumin cDNA. This 
plasmid was validated against serial dilutions of B7 cells containing a single integrated copy of 
SIVsmB7 (173)  by using TaqMan real-time PCR with primers 5’-
TTGAGCCCTGGGAGGTTCT-3’ and 5’-CCAAGTGCTGGTGAGAGTCTAG-3’, and probe 
5’-CAGCACTAGCAGGTAGAGCCTGGGTGTTC-3’, and used as a standard for calculating 
the frequency of infection in sorted cells.  SIVmac251 gag copy number in each DNA sample 
was quantified by comparison with serial dilutions of the plasmid standard using TaqMan real-
time PCR using primers 5’-GCCAGGATTTCAGGCACTGT-3’ and 5’-
GCTTGATGGTCTCCCACACAA-3’, and the probe 5’-
AAGGTTGCACCCCCTATGACATTAATCAGATGTTA-3’ specific for sequences of gag that 
are conserved across SIV strains.  In parallel, the albumin gene copy number was determined to 
quantify the number of cells loaded in each reaction using primers 5’-
TGCATGAGAAAACGCCAGTA-3’ and 5’-AGCATGGTCGCCTGTTCAC-3’ and probe 5’-
AAAGTCACCAAATGCTGCACGGAATCC-3’.  Reactions were performed in duplicate using 
TaqMan Universal mix kit (Applied Biosystems), 200 nM of each primer and 125 nM probe, at 
95°C for 10 min, with 40 cycles of 95°C, 15 s and 60°C, 1 min using the Prism 7900H sequences 
detection system (Applied Biosystems). 
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5.4.6 Statistical analysis 
Differences between pre and post-infection time points were determined using the nonparametric 
Wilcoxon signed-rank test.  Cross-sectional analysis of SIV-naïve and animals with acute SIV 
infection were performed using the nonparametric Mann-Whitney U test.  Correlations were 
determined using the non-parametric Spearman rank test.  Multiple comparisons between the 
frequencies of SIV infection in sorted populations were performed using the Kruskal-Wallis test 
followed by Dunn’s post test.  All statistical comparisons were considered significant when two-
tailed P < 0.05. 
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 5.5 RESULTS 
5.5.1 Rapid loss of pDC from blood and lymph node during acute SIV infection 
In order to document changes in pDC number in blood during HIV infection, we used the rhesus 
macaque model of intravenous infection with the pathogenic isolate SIVmac251.  Infection 
resulted in detectable viremia within 3 days post infection that plateaued at day 12 and was 
associated with an expected decline in the number of blood CD4+ T cells by day 10 post 
infection (Fig. 15).  pDC were identified within the CD45+ mononuclear cell fraction of blood as 
Lineage (CD3, CD14, CD20)–  HLA-DR+ CD123+ cells using flow cytometry (Fig. 14A) (85) 
and enumerated by an indirect method using TruCOUNT beads as described in the Methods 
section. In contrast to CD4+ T cells, there was a significant increase in the number of blood pDC 
between 3 and 6 days post infection, in some instances reaching 7 times that of pre-infection 
levels, indicative of peracute mobilization of pDC (Fig. 14B).  This was followed at day 10 by a 
significant decrease in pDC number from baseline which remained suppressed until at least day 
14 (Fig. 14B), when CD4+ T cells had begun to recover (Fig. 15).  The absolute number of pDC 
in blood was inversely correlated with plasma viral load and positively correlated with CD4+ T 
cell number during the course of primary SIV infection (Fig. 14C).  To determine whether the 
drop in pDC from blood at days 10-14 of infection was associated with an increase in pDC 
number in lymph nodes, we harvested axillary lymph nodes at 14 days post infection and 
determined the proportion and absolute number of pDC in cell suspensions. pDC were identified 
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as HLA-DRlow CD123+ cells within the Lineage– HLA-DR+ DC fraction following exclusion of 
dead cells based upon staining with an amine-reactive viability dye (Fig. 14D) (85).  
Surprisingly, both the percentage of pDC within the DC fraction and the absolute number of 
pDC per unit weight of tissue were markedly decreased in SIV-infected lymph nodes as 
compared to naïve controls (Fig. 14E).  These findings indicate that acute SIV infection results in 
a bimodal pDC response in blood, with rapid pDC increases followed by loss, and that this loss 
is paralleled by depletion of pDC from lymph nodes. 
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 Figure 14. pDC are transiently increased and then lost from blood and lymph nodes in acute SIV 
infection 
 
A, Representative contour plots demonstrating the gating strategy used to define pDC within the mononuclear cell 
fraction (MNC) of freshly isolated peripheral blood leukocytes.  B, Absolute number of pDC in blood during acute 
SIV infection over all days (left) and comparing pre-infection to peak responses at day 3 or 6 (right). Symbols 
represent individual animals with the baseline number of pDC/μL blood prior to infection (day 0) representing the 
median of 4 independent measurements for each animal.  C, The number of pDC in blood was inversely correlated 
with viral load and positively correlated with CD4+ T cell counts during the 14-day period.  D, Representative plots 
demonstrating the gating strategy used to delineate the Lineage– HLA-DR+ fraction and CD123+ pDC in axillary 
lymph node cell suspensions.  E, Number of pDC in lymph nodes of naïve animals and animals at 14 days post-
infection expressed as percent of pDC within the Lineage– HLA-DR+ fraction (left) and as absolute number of 
pDC/gram of tissue (right).  Symbols represent individual animals and horizontal lines represent medians. 
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 Figure 15. High dose intravenous SIVmac251 infection leads to dramatic loss of mononuclear and 
CD4+ T cells 
 
A, Viral RNA copy/mL of plasma was determined following 1000 TCID50 SIVmac251 infection using real-time RT-
PCR.  Symbols represent individual animals and error bars the 95% confidence interval of samples run in duplicate. 
B, Changes in the absolute number of CD4+ T cells/μL of blood for all animals during acute SIV-infection using BD 
TruCOUNT tubes.  Day 0 represents the median number of cells from at least 4 independent measurements prior to 
infection including day 0.  Symbols represent individual animals (left panel) and the group median + 95% 
confidence interval (right panel).  The dashed line represents the overall group median baseline cell number/μL of 
blood.  Each timepoint starting on day 10 was significantly decreased compared to pre-infection. 
 
5.5.2 Acute SIV infection does not alter the frequency of pDC in bone marrow  
The depletion of pDC from both blood and lymph nodes during acute SIV infection could be 
explained by bone marrow suppression leading to a loss of pDC production.  To address this 
possibility we analyzed the frequency of phenotypically-defined pDC in paired bone marrow 
samples taken prior to and 12 days following SIV infection.  pDC were identified within the 
Lineage– HLA-DR+ fraction of bone marrow mononuclear cells by expression of CD123 (Fig. 
16A), as has previously been described (174).  The frequency of total mononuclear cells was 
unchanged in bone marrow in response to SIV infection, and the proportion of pDC within this 
cell population as well as the total pDC number per volume of bone marrow aspirate were also 
unaffected by infection (Fig. 16B).  We next analyzed bone marrow pDC for expression of the 
nuclear proliferation antigen Ki-67, which is expressed by cells in a non-G0 phase of the cell 
cycle and thus provides an approximation of the recent proliferative history of a given cell 
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population (175).  The majority of bone marrow pDC in SIV-naïve animals were Ki-67+ 
reflecting a high rate of production (55) and this was unchanged as a result of SIV infection (Fig. 
16C). These data indicate that acute SIV infection does not alter pDC production or dynamics in 
bone marrow, consistent with the findings of others (174). 
 
Figure 16. Normal pDC production from bone marrow in acute SIV infection 
A, Representative contour plots demonstrating the gating strategy used to define pDC within the mononuclear cell 
(MNC) fraction of bone marrow aspirates.  B, Paired analyses of the absolute number of MNC in bone marrow 
(left), the frequency of pDC within the total MNC fraction (middle) and the absolute number of pDC in bone 
marrow (right) before and 12 days after SIV infection. Symbols represent individual animals. C,  pDC were gated as 
in (A) and the percentage of pDC expressing Ki-67 determined by comparing to staining with an isotype control 
antibody (left).  Contour plots represent an analysis at day 12 post infection and numbers represent the percentage of 
cells within the indicated gates.  Paired analysis of the percentage of Ki-67+ pDC before infection and at day 12 
post-infection (right). NS = not significant. 
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5.5.3 Rapid mobilization of pDC into blood during acute SIV infection  
The rapid but transient increase in the number of pDC in blood together with normal pDC 
frequencies in bone marrow raised the possibility that pDC were being actively mobilized from 
bone marrow into blood during acute SIV infection.  To address this we first analyzed blood 
pDC for expression of Ki-67, which provides an indication of the pDC fraction that was recently 
mobilized from bone marrow.  Prior to SIV infection, the mean percentage of Ki-67+ pDC was 
52% (Fig. 17, A and B), indicating that half of all pDC in the circulation were recently released 
from bone marrow.  However, by day 14 post infection 87% of circulating pDC expressed Ki-67 
indicative of mobilization (Fig. 17B), and this increase was inversely correlated with the absolute 
number of blood pDC (Fig. 17C).  To accurately determine the rate of mobilization of pDC into 
blood we administered BrdU by intravenous injection at days 10, 11, 12 and 13 post infection 
and sampled blood 24 hours after each administration.  BrdU is only incorporated into cells 
undergoing S-phase of the cell cycle during the time of delivery, and hence BrdU+ pDC in blood 
will be marked as having been released from bone marrow since the time of the BrdU pulse.  In 
SIV-naïve monkeys only 2% of blood pDC were BrdU+ at 24 hours after the first pulse, reaching 
a maximum of 13% after the fourth pulse, indicating a relatively low rate of pDC mobilization in 
health (Fig. 17, D and E).  In stark contrast, upwards of 20% of blood pDC from SIV-infected 
animals at day 11 were BrdU+ after a single BrdU pulse and this approached 60% after the fourth 
pulse at day 14 post infection (Fig. 17, D and E).  The degree of Ki-67 staining and BrdU 
incorporation at day 14 were strongly correlated (Fig. 17F).  These findings indicate that acute 
SIV infection results in rapid mobilization of pDC into blood that is quickly obscured by 
declining pDC numbers. 
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 Figure 17. Rapid mobilization of pDC into blood during acute SIV infection 
A, Representative contour plots from an animal prior to infection demonstrating the gating strategy used to identify 
Ki-67+ pDC in blood.  pDC were gated as in Fig. 1 and  Ki-67 positivity determined based on the level of 
background fluorescence using the isotype-matched control antibody.  Numbers represent the percentage of cells 
within the indicated gates.  B, Paired analysis of percentage of Ki-67+ pDC in blood prior to infection and at day 14 
after infection. Symbols represent individual animals.  C, The absolute number of pDC in blood was inversely 
correlated with the percentage of cells expressing Ki-67. Shown are data from individual animals prior to infection 
and 14 days after infection .  D, Representative contour plots demonstrating the gating strategy used to identify 
BrdU+ pDC prior to and 24-hour after four consecutive intravenous daily injections of BrdU in an SIV-naive and 
SIV-infected macaque.  BrdU was delivered starting on day 10 of infection.  Numbers represent the percentage of 
BrdU+ pDC within each gate.  E, The percent of BrdU+ pDC in blood of SIV-naïve animals (dashed lines) and SIV-
infected animals (solid lines) 24 hours after each BrdU pulse. F, The percent of BrdU+ pDC was positively 
correlated with the percent of Ki-67+ pDC 24 hours after the final BrdU administration. 
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5.5.4 Massive recruitment of pDC into peripheral lymph nodes during acute SIV 
infection 
We next used BrdU incorporation and Ki-67 staining to investigate whether increased 
mobilization of pDC into blood was paralleled by recruitment of pDC to lymph nodes, despite 
the loss of pDC from these tissues.  Axillary lymph nodes were harvested from SIV-infected 
monkeys at day 14 post infection and from SIV-naïve monkeys receiving the same course of 
BrdU and pDC were analyzed for BrdU incorporation (Fig. 18A). Only 2% of lymph node pDC 
were BrdU+ after 4 pulses of BrdU in SIV-naïve monkeys, indicating a low level of pDC 
recruitment into normal lymph nodes.  However, 19% of lymph node pDC from SIV-infected 
monkeys were BrdU+, representing a ~10-fold increase in pDC recruitment over the 4-day 
labeling period relative to controls (Fig. 18B).  Similarly, the mean proportion of lymph node 
pDC that were Ki-67+ in SIV-naïve monkeys was only 2.5%, whereas more than 50% of lymph 
node pDC from monkeys at day 14 post infection stained for Ki-67.  This represents a 20-fold 
increase in recently-divided pDC within lymph nodes as a result of SIV infection (Fig. 18, C and 
D).  In fact, whereas the total number of lymph node pDC declined in acute SIV infection (Fig. 
14E) the number of Ki-67+ pDC in lymph nodes was significantly increased over SIV-naïve 
lymph nodes (Fig. 18D).  Nevertheless, the proportion of pDC that expressed Ki-67 had a strong 
inverse correlation with the total number of pDC in lymph nodes, indicating that recruitment and 
loss were occurring concurrently (Fig. 18E).  Together, these data demonstrate that pDC undergo 
a marked recruitment to peripheral lymph nodes during acute SIV infection but that the net result 
is an overall loss of pDC from these tissues.  
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 Figure 18. Massive recruitment of recently mobilized pDC to peripheral lymph nodes in acute SIV 
infection 
 
A, Representative plots demonstrating the gating strategy used to identify pDC in CD20-depleted axillary lymph 
nodes (left). Representative plots of BrdU staining in a SIV-naïve and SIV-infected macaque (right).  Numbers 
represent the percent of cells within the indicated gate.  B, Percent of BrdU+ pDC in lymph nodes 24 hours after the 
final BrdU pulse in naïve and infected animals.  Symbols represent individual animals and horizontal bars represent 
medians. C, Representative plots demonstrating Ki-67 staining in pDC as gated in (A).  D,  Number of Ki-67+ pDC 
in lymph nodes from SIV-naive animals and animals at day 14 post-infection expressed as a percent of all pDC (left) 
and as absolute number/gram of tissue (right).  Symbols represent individual animals and horizontal bars represent 
medians. E, The frequency of pDC within the Lin– HLA-DR+ gate is inversely correlated with the percent of Ki-67+ 
pDC in lymph nodes.  Symbols represent individual SIV-naive animals and animals at 14 days post infection.    
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5.5.5 Activation, infection and death of pDC in lymph nodes during acute SIV infection 
The overall loss of pDC from lymph nodes despite their massive recruitment strongly suggests 
that pDC are dying in these tissues during infection.  To examine this directly, we first stained 
lymph node cell suspensions with antibodies to define pDC and then measured the proportion of 
cells that were dead based on staining with the amine-reactive viability dye.  Nearly 15% of pDC 
from lymph nodes taken at 14 days post infection were non-viable as compared to 3% of pDC 
from naïve lymph nodes (Fig. 19A).  This increase was due to an increase in late apoptosis and/or 
necrosis based on pDC co-labeling with Annexin V and 7-AAD (Fig. 19B).  These data indicate 
that pDC resident in lymph nodes are more likely to be apoptotic or necrotic as a result of acute 
SIV infection.  To determine whether direct virus infection could play a role in pDC death, we 
stained lymph node cell suspensions with antibodies and simultaneously sorted pDC as 
Live/Dead– Lineage– HLA-DR+ CD123+ CD11c– cells and myeloid DC (mDC) as Live/Dead– 
Lineage– HLA-DR+ CD123– CD11c+ to at least 95% purity (Fig. 19C).  SIV gag DNA was then 
measured in total cellular DNA from these cells using gag primers and probe by quantitative 
PCR and the frequency of infected cells determined on the basis of albumin DNA quantity, as 
described in the Methods section (7).  In separate tubes we sorted CD4+ T cells as Live/Dead– 
CD3+ CD4+ cells and determined their frequency of SIV infection.  These data revealed that 
more than 4% of lymph node pDC harbored SIV gag DNA at day 14, reaching up to 15% in one 
animal, a frequency that was slightly greater than SIV-infected CD4+ T cells and well above that 
of the unseparated lymph node fraction (Fig. 19C).  In contrast, mDC had almost undetectable 
levels of gag DNA (Fig. 19C).  The negligible infection of mDC confirms that the pDC result 
was not due to contaminating CD4+ T cells, as mDC and pDC were sorted simultaneously from 
the same tubes.  To investigate whether indirect mechanisms of pDC death may also contribute 
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to the significant cell death seen in lymph nodes, we measured expression of known pro-
apoptotic tumor necrosis factor (TNF) family members CD95 (Fas), TNF-related apoptosis-
inducing ligand (TRAIL) and the TRAIL receptor death receptor (DR) 5 by flow cytometry. 
These data revealed that lymph node pDC from SIV-naïve monkeys had almost undetectable 
expression of CD95, whereas CD95 was uniformly expressed by pDC from SIV-infected lymph 
nodes, indicative of activation (176) (Fig. 19D).  However, we were not able to detect 
differences in apoptosis of lymph node pDC from uninfected or infected monkeys after 
incubation with CD178 (Fas ligand; data not shown), consistent with earlier reports (78).  No 
expression of TRAIL or DR5 was detected on lymph node pDC regardless of SIV infection 
status (data not shown).  These data show that pDC in lymph nodes of monkeys with acute SIV 
infection are activated and have increased death through apoptosis and necrosis, and that a 
significant fraction of pDC are infected with virus. 
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 Figure 19. Activation, infection and death of pDC in SIV-infected lymph nodes 
A, Representative contour plots demonstrating staining of pDC from CD20-depleted axillary lymph nodes from SIV-
naïve and SIV-infected animals with the amine-reactive Live/Dead viability dye (left).  pDC were gated as in Fig. 4.  
Numbers represent the percentage of non-viable pDC.  Percent of non-viable pDC in lymph nodes of SIV-naive 
animals and animals at 14 days post-infection (right).  Symbols represent individual animals and horizontal lines 
represent medians.  B, Representative contour plots demonstrating the quadrant gates used to define early apoptotic 
(Annexin V+/7-AAD–) and late apoptotic/necrotic (Annexin V+/7-AAD+) pDC from lymph nodes from SIV-naive 
and SIV-infected animals (left).  Numbers represent the percent of cells in respective quadrants.  Percent of late 
apoptotic/necrotic pDC in lymph nodes from SIV-naive animals and animals at 14 days after infection (right). 
Symbols represent individual animals and horizontal lines represent medians.  C, Representative dot plots 
demonstrating pDC and mDC in the Lineage– HLA-DR+ gate prior to and after sorting from the axillary lymph node 
of a monkey 14 days after infection (left).  Numbers in parentheses indicate the purity of mDC and pDC.  Sorted 
cells were spun onto slides and stained with Wright Giemsa stain.  Frequency of total lymph node (LN) cells or 
sorted mDC, pDC and CD4+ T cells containing proviral DNA as determined by quantitative PCR (right).  *P < 0.05, 
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***P < 0.001.  Symbols represent individual animals and horizontal lines represent medians.  D, Lymph node pDC 
were analyzed for surface CD95 expression.  Representative histograms demonstrating CD95 expression (solid 
histogram) compared to isotype control (dotted line) in naïve and SIV-infected lymph nodes (left).  Numbers 
represent percent of CD95+ cells.  Percent of CD95-expressing pDC in lymph nodes of SIV-naive macaques and 
animals with acute SIV infection.  Symbols represent individual animals and horizontal lines represent medians. 
 
 
5.5.6 Blood and lymph node pDC have largely normal function in acute SIV infection 
We next examined the function of pDC in blood and lymph nodes during acute SIV infection. 
Given that SIV and HIV stimulate pDC in large part through Toll-like receptor 7 (TLR7)(79, 
171), we analyzed pDC function by stimulating cells through TLR7 engagement using the 
TLR7/8 agonist 3M-007.  We did a short-term stimulation of unseparated PBMC taken before 
infection or at day 14 post infection with 3M-007 and determined expression of TNF-α by flow 
cytometry, gating on CD123+ pDC (Fig. 20A).  Between 20% and 40% of pDC in blood 
produced TNF-α in response to TLR7 stimulation regardless of infection status (Fig. 20A).  We 
next stimulated CD20-depleted lymph node cells taken from SIV-naïve monkeys or monkeys at 
14 days post infection and stimulated them in the same manner, this time analyzing cells for 
expression of IFN-α and TNF-α.  Approximately half of all lymph node pDC produced both 
TNF-α and IFN-α in response to this stimulation regardless of whether lymph nodes were taken 
from SIV-naïve or SIV-infected monkeys, whereas endogenous cytokine production in the 
absence of stimulation was negligible (Fig. 20B and data not shown).  Interestingly, the small 
proportion of pDC producing IFN-α alone was undiminished by SIV infection, although lymph 
node pDC from SIV-infected monkeys had a reduced capacity to produce TNF-α alone (Fig. 
20B).  These findings indicate that despite a net loss of pDC the remaining cells in blood and 
lymph node retained largely normal functional responses to TLR7 stimulation during primary 
SIV infection. 
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 Figure 20. pDC retain largely normal function in response to TLR7 stimulation during acute SIV 
infection 
 
A, Contour plots demonstrating the gating strategy used to identify TNF-α+ pDC in PBMC from SIV-naïve and SIV-
infected monkeys following stimulation with 3M-007 (left).  Numbers represent the percentage of TNF-α+ pDC 
within the indicated gates.  Percent of TNF-α+ pDC in PBMC from SIV-naïve and SIV-infected monkeys in 
response to media or 3M-007 (right).  Bars represent the median and error bars the 95% confidence interval. 
B, Representative contour plots demonstrating the gating strategy used to identify TNF-α+, IFN-α+, or TNF-α+/ IFN-
α+ pDC in lymph nodes following 3M-007 stimulation in the absence or presence of Brefeldin A (BFA) (left).   
Numbers in parentheses represent the percentage of cells expressing the respective cytokines.  Percent of lymph 
node pDC from SIV-naïve and SIV-infected monkeys expressing TNF-α, IFN-α, or both in response to TLR7/8 
agonist (right).  Bars represent the median and error bars the 95% confidence interval. 
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5.6 DISCUSSION 
In this study we used rhesus macaques infected with the pathogenic SIVmac251 strain to model 
kinetics of the acute pDC response to HIV infection of humans.  We combined enumeration of 
cells in blood and lymphoid tissues with BrdU incorporation and Ki-67 staining to document 
pDC production.  Since pDC are generated in bone marrow and enter the blood as end stage cells 
without further replication in tissues (55) we were to able to use these complementary 
approaches to effectively track pDC from bone marrow to blood and then to lymph nodes and to 
relate this migration to changes in cell number over time.  
  
Our findings reveal a rapid and highly dynamic pDC response to SIV infection with mobilization 
of cells into blood occurring as soon as 3 days after intravenous virus challenge.  By 11 days 
after infection around 20% of blood pDC had mobilized from bone marrow in the previous 24-
hour period following a single BrdU administration, and this reached 60% by day 14 after four 
administrations of BrdU.  In fact this is likely to be an underestimate of the extent of pDC 
mobilization given that BrdU has a half-life of only 2 hours in the circulation (177).  This 
mobilization is likely the result of increased systemic TNF-α (178) which has been shown to 
control pDC mobilization in murine models (63).  By days 10 to 14 of infection the number of 
pDC in blood had dramatically declined despite normal production from bone marrow, 
coincident with massive recruitment of pDC to lymph nodes.  At day 14 of infection the 
proportion of lymph node pDC that had recently been released from bone marrow as determined 
by Ki-67 staining or BrdU incorporation was 20-fold greater than that of naïve monkeys, 
reaching 50% of all cells.  Rapid pDC recruitment is consistent with the TNF-α-driven 
expression of CXCL9 and upregulation of CCL19 in lymph nodes (63, 103, 104, 179) and 
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induction of CCR7 on activated pDC in the circulation (50, 171).  These data show that the 
inflammatory response in acute SIV infection is highly effective at inducing the coordinated 
mobilization and recruitment of large numbers of pDC into blood and lymph nodes.  
 
Paradoxically, pDC recruitment was occurring as pDC numbers in lymph nodes were 
dramatically declining, indicating that cells were dying at a rate faster than they could be 
replenished.  Rapid influx of pDC to lymph nodes at a time when virus is highly concentrated in 
these tissues (180) would increase the potential for pDC to virus-infected CD4+ T cell contact, 
potentially leading to death by apoptosis and necrosis (78).  Consistent with this possibility, we 
found around 15% of pDC undergoing late apoptosis and/or necrosis in acutely infected lymph 
nodes.  In addition, high virus levels in lymph nodes would promote direct infection of pDC, and 
we show that a fraction of pDC harbored proviral DNA.  Therefore, viral infection of pDC had 
occurred and proceeded at least to the point of reverse transcription.  While the frequency of 
infected pDC was relatively modest at 4% it was similar to that of CD4+ T cells, the principle 
cells infected in lymph nodes at this time (181), suggesting that pDC are a significant target of 
virus infection.  Previous reports have described Gag-expressing pDC in lymphoid tissues and 
pDC harboring proviral DNA in blood of HIV-infected individuals (40, 96), but up to now the 
efficiency of pDC infection in vivo was not known.  By contrast, the frequency of infected mDC 
was almost below detection, indicating that these cells may not be a significant source of virus in 
lymph nodes (182).  While limited cell numbers did not allow us to directly determine whether 
infection resulted in cell death, in vitro data indicate that pDC infection concurrent with 
activation through CD40L results in giant cell formation and death (97).  In vivo, activated CD4+ 
T cells that engage infected pDC in the lymph node paracortex would provide CD40L.  
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Furthermore, Gag-expressing CD123+ multinucleated giant cells have been identified in HIV-
infected lymphoid tissues (96), consistent with the notion of virus-induced pDC death.  It is 
possible that the inflammatory environment in the lymph node also impacts pDC survival via 
factors that remain to be defined.  pDC from SIV-infected lymph nodes uniformly expressed 
CD95, and in mice exposed to inflammatory and microbial stimuli CD95 expression induced on 
activated pDC is linked to apoptotic cell death (176).  However, while CD95/CD178 interactions 
play a role in CD4+ T cell loss in HIV and SIV infection (115, 183) the role for this pathway in 
pDC death is yet to be established (78).  
 
Our data strongly support the hypothesis that the physiologic response of pDC to enter inflamed 
lymph nodes is actually deleterious in immunodeficiency virus infection as it brings pDC into an 
environment rich with virus, virus-infected cells and pro-apoptotic factors that lead to cell death.  
Depletion of pDC from lymphoid tissues subsequent to recruitment is likely to have a significant 
impact on virus control at a number of levels.  Activated pDC directly suppress HIV replication 
in CD4+ T cells (78) and can stimulate antigen-specific CD4+ T cell responses (50).  Virus-
exposed pDC induce maturation of mDC in vitro, and pDC cooperate with mDC in the induction 
of virus-specific cytotoxic T cell responses in vivo (50, 80).  Type I IFN production by pDC 
inhibits HIV replication (77) but also may have a harmful effect by promoting TRAIL expression 
and subsequent apoptosis of CD4+ T cells (184).  
 
Nonpathogenic SIV infection of sooty mangabeys is characterized by lower levels of chronic 
immune activation than SIV infection of rhesus macaques (185), and a recent study has 
suggested that this lack of pathogenicity is due in part to muted pDC homing to lymph nodes 
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together with an inability of pDC to respond appropriately to SIV stimulation in this species 
(171).  However, these findings conflict with studies using a similar nonpathogenic model of SIV 
infection in African green monkeys that revealed a significant increase in the number of pDC in 
lymph nodes concurrent with increased IFN-α production during acute infection (89).  Hence the 
potential for pDC recruitment and activation in these nonpathogenic models remains unclear. In 
addition, data from other pathogenic SIV models, including SIVsm infection of rhesus macaques 
and SIVmac251 infection of cynomolgus macaques, suggest that acute infection may be 
associated with increased numbers of pDC in lymph nodes (84, 171).  While it is difficult to 
directly compare data generated using different virus strains and species of monkey, it is 
apparent from our studies that enumeration of cells by itself provides limited information about 
pDC kinetics.  It is likely that massive pDC recruitment to inflamed lymph nodes during acute 
infection in some pathogenic SIV models compensates for and masks an underlying pDC death 
within tissues for a period of time.  However, our data would indicate that newly-arrived cells 
would have a short life span within the hostile environment of the lymph node and may therefore 
have limited opportunity to function.  Ultimately, pDC death exceeds replenishment as infection 
progresses, leading to the substantial pDC depletion from lymph nodes consistently observed in 
chronic HIV and SIV infection (54, 85, 186).   
 
Reduction in circulating type I IFN in HIV infected individuals is correlated with pDC loss and 
is generally thought to be due to impaired pDC function (46, 87, 91, 92, 169, 187), although this 
is rarely studied directly.  In our study, pDC from blood and lymph nodes in monkeys with acute 
SIVmac251 infection were largely normal in their response to TLR7 stimulation, with lymph 
node pDC producing TNF-α and IFN-α together at high levels that were indistinguishable from 
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controls.  It is possible that pDC function early in infection remains intact, and studies of HIV-
infected patients indicate that impaired production of IFN-α by pDC is most apparent in 
individuals with advanced disease (91).  Whether IFN-α production by the limited number of 
surviving pDC in acute infection is sufficient to induce chronic CD4+ T cell activation in lymph 
nodes, as has recently been proposed (171, 188), remains to be determined. 
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6.0  OVERALL DISCUSSION 
The rhesus macaque/SIV model is useful for elucidating the pathogenesis of HIV and subsequent 
development of efficacious vaccines derived from analyses of SIV infected nonhuman primates.  
Depletion of mDC and pDC has been well documented in HIV-infected patients although the 
underlying mechanism of loss has not been defined.  Primate models of HIV infection provide a 
means to study the dynamics of DC following viral infection in multiple tissue compartments not 
readily available for study in humans.  Moreover, phenotypic and functional counterparts of 
human DC have been identified in rhesus macaques.   
 
The aims of the current proposal were to: 1) determine whether rhesus macaque DC could be 
further defined into phenotypically distinct subsets similar to humans, 2) determine whether DC 
were recruited to lymphoid tissues during simian AIDS and 3) determine the dynamic pDC 
response during acute SIV infection taking into account pDC production, mobilization, 
recruitment, infection and death.      
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6.1 PHENOTYPIC DEFINITION OF RHESUS MACAQUE mDC 
 
Human blood contains four distinct non-overlapping subsets of pDC (one) and mDC (three) (25).  
Similar to humans, rhesus macaque pDC were phenotypically homogeneous and defined as CD3, 
CD14, CD20 – negative (Lin-) HLA-DR+ CD123+ cells lacking expression of CD11b, CD56, 
CD8, and CD16, representing approximately 3% of the DC fraction in blood.  The three 
phenotypically distinct human mDC subsets are defined as within the DC fraction of blood as 
CD1b/c+, CD16+ and BDCA-3+ with all three containing a fraction of CD56+ cells (25).  In 
contrast to human mDC subsets, nearly 100% of macaque mDC expressed CD16 (FcγRIII), 
traditionally believed to only be expressed by rhesus NK cells (132) and a minor fraction of 
monocytes, similar to humans (139, 189, 190).  However, rhesus CD16+ mDC expressed 
moderate levels of CD11b and CD56, characteristic markers of monocytes and a minor subset of 
NK cells (132, 133).  In contrast to human mDC, rhesus mDC did not express CD1c.  However a 
subset of rhesus B cells were found to express CD1c, consistent with human B cells (138).  
Therefore, rhesus macaque mDC are phenotypically similar to human mDC expressing CD56 
and CD16 but are largely defined as a single phenotypic subset.    
 
The finding that rhesus macaque mDC express CD16 raises a few points for consideration.  
Treatment of macaques with CD16-depleting mAbs would not only remove the majority of 
CD16+ NK cells but also CD16+ mDC making it difficult to discern the role of NK cells alone in 
the pathogenesis of SIV infection (141, 191).  In addition, phenotypic identification of NK cells 
as CD3-CD16+ cells would also include mDC, leading to discrepancies in alterations of absolute 
NK cell numbers (140).  Importantly, inclusion of CD16 as a lineage marker would exclude both 
 95 
NK cells and mDC as lineage-positive cells resulting in dramatic reductions in absolute mDC 
numbers (114), inconsistent with findings from other studies (17, 85). 
6.2 LOSS OF mDC IN BLOOD DURING SIMIAN AIDS 
 
Consistent with findings in HIV-infected individuals, circulating mDC were depleted in rhesus 
macaques with simian AIDS.  This loss has been hypothesized to be due to the redistribution of 
mDC to peripheral lymphoid tissues based on the bystander maturation of mDC leading to 
upregulation of functional CCR7 (50).  However, we found no evidence of mDC recruitment to 
peripheral lymphoid tissues such as axillary and mesenteric lymph nodes or spleen in rhesus 
macaques with simian AIDS.  The majority of mDC in lymph nodes expressed the Langerhans 
cell marker CD1a, indicating they were derived from DC in peripheral tissues not blood.  
However, following mammary tumor virus infection, mDC migrate directly from blood into 
lymph nodes by a L-selectin-dependent mechanism (192), leaving open the possibility that mDC 
migrate directly to lymph nodes through high endothelial venules (HEV).  Nevertheless, the 
increased death of mDC during simian AIDS may occur faster than recruitment, resulting in the 
net loss of cells observed.  In vitro studies have shown that mDC are weakly activated by 
exposure to HIV (98) and undergo bystander maturation induced by pDC-derived IFN-α (50).  In 
chronic HIV, IFN-α production by pDC is impaired supporting the lack of mDC activation and 
recruitment to lymph nodes in vivo.  Circulating mDC in animals with AIDS showed no evidence 
of increased maturation or costimulatory molecule expression and splenic DC from HIV+ 
patients displayed a normal phenotype, showing no signs of in vivo activation but impaired 
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maturation following culture (145).  However, in HIV-1 viremic patients, increased 
costimulatory molecule expression has been observed (39, 41), leaving the effect of HIV or SIV 
on mDC activation unclear.  
6.3 LOSS OF MIGRATORY DC DURING SIMIAN AIDS  
Previously, we have shown that a significant factor in the loss of mature DC in lymph nodes may 
be impaired trafficking of DC from epithelial surfaces (52).  Consistent with this finding, the 
predominant mDC population lost from lymph nodes of monkeys with AIDS was the mature, 
CD1a+ skin derived DC.  The mechanism underlying suppressed migration remains unknown, 
although it is unlikely due to direct viral infection of DC (52).  HIV and SIV are able to infect 
Langerhans cells (166, 167) however evidence for significant infection of Langerhans cells 
during advanced disease is lacking.  In addition, Langerhans cell migration is unaltered during 
acute SIV infection when virus load is at its peak (52) and less than 1% of lymph node mDC, the 
majority being migratory DC, contained evidence direct SIV infection.  In SIV-infected 
macaques with AIDS, expression of the CCR7 ligand, CCL21/6Ckine is reduced in lymph nodes 
(179) likely contributing to the loss of migratory CD1a+ DC.  Preliminary experiments using 
autologous delivery of in vitro matured monocyte-derived DC have demonstrated normal 
trafficking of injected cells to draining lymph nodes.  This indicates that the chemokine network 
required for DC migration is relatively intact in monkeys with AIDS (data not shown).  Thus, it 
is likely that the cytokine milieu of the skin and possibly other epithelial surfaces are involved in 
the failure of DC migration and loss in lymph nodes as discussed elsewhere (52).  Increasing 
evidence suggests mDC are important in the induction of HIV-specific CD4+ T cell responses 
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(50).  Therefore, loss of mDC in advanced HIV infection would clearly reduce the capacity to 
respond to HIV or opportunistic infections, contributing to the onset of immunodeficiency. 
6.4 INCREASED FREQUENCY OF ‘IMMUNOSUPPRESSIVE’ DC DURING AIDS 
In contrast to the reduction of DC in lymph nodes of monkeys with AIDS, we observed an 
increase in a population of Lin- HLA-DRmodCD11c-CD123- cells within the DC fraction of 
lymph nodes that morphologically resembled monocytoid cells.  Overnight culture of rhesus 
macaque blood DC lacking CD11c or CD123 in GM-CSF and IL-4 resulted in the majority of 
these cells acquiring an mDC phenotype (17).  Interestingly, similar culture conditions failed to 
induce further differentiation of Lin- HLA-DRmod cells or increase cell survival, indicating GM-
CSF and IL-4 are not survival factors.  Although the origin of these cells remains undefined, an 
increased frequency of circulating blood DC lacking CD11c and CD123 expression eliciting 
poor T cell proliferation and IFN-γ secretion has been identified in cancer patients (128).  In 
addition, a similar population of cells has been identified in lymph nodes from patients with 
chronic HIV which induced allogenic T cells to develop a regulatory phenotype (168).   The low 
CD86 and lack of CD80 expression of the Lin- HLA-DRmodCD11c-CD123- cells in lymph nodes 
or animals with AIDS is consistent with regulatory rather than immunostimulatory DC. 
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6.5 pDC LOSS DURING ACUTE SIV INFECTION 
To further elucidate the possible mechanisms of DC loss, we focused our final studies on pDC 
dynamics during the first two weeks of highly pathogenic SIV infection.  Our findings 
demonstrate that rapid pDC increases were followed by depletion during primary SIV infection 
despite active mobilization from bone marrow and migration to lymph nodes.  Repeated 
sampling over short time intervals revealed a rapid bimodal pDC response with depletion below 
steady state levels within 10 days of SIV infection.  Importantly, the well-defined sustained 
reduction of blood pDC numbers in both HIV and SIV infection after peak viremia indicates the 
early events of infection may influence pDC frequency in the chronic phase (45, 54, 85, 169), 
similar to the massive depletion of memory T cells (7).  Comparatively, nonpathogenic infection 
of African green monkeys leads to reduced frequencies of pDC in blood but increases in lymph 
node and IFN-α production followed by complete pDC recovery, highlighting that pDC loss 
likely plays a critical role in disease pathogenesis (89).  
 
Consistent with the observed phenotypic and functional activation of HIV-1 exposed pDC (50, 
68) and increased levels of inflammatory chemokines (103, 179), pDC were actively recruited to 
lymph nodes following pathogenic SIV infection.  Considering the balance of pDC in blood and 
lymph nodes, we cannot exclude the possibility that sustained loss of circulating pDC in blood is 
partially due to both lymph node recruitment as well as death.  Bone marrow from animals 
infected with SIV contained pDC frequencies similar to pre-infection indicating pDC depletion 
was not due to a primary defect in hematopoiesis supporting the effective mobilization of pDC 
from bone marrow in SIV-infected macaques(114).  Our results point to the sustained reductions 
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in blood pDC reflect the inability of pDC production and mobilization to keep pace with lymph 
node recruitment and death.  
 
Investigation of pDC dynamics using BrdU and Ki-67 provides initial evidence that pDC 
depletion is coupled with profound increases in mobilization from bone marrow as well as lymph 
node recruitment during acute SIV infection.  The strong correlation between in vivo BrdU 
labeling and Ki-67 expression by pDC indicates future studies may incorporate Ki-67 as a 
relative indicator of changes in pDC mobilization and lymph node recruitment during viral 
infection. 
6.6 ROLE OF DIRECT VIRAL INFECTION IN DC LOSS 
Circulating mDC express the viral receptor and coreceptor, CD4 and CCR5, suggesting direct 
viral infection may lead to mDC loss.  mDC are susceptible to both CCR5 and CXCR4-tropic 
HIV in vitro (98, 99) and mDC from untreated HIV-infected individuals show evidence of 
infection in vivo (40).  Although the frequency of infection of blood mDC is not known, splenic 
DC are known to harbor 10 to 100 times less HIV DNA than infected CD4+ T cells (163). 
Furthermore, DC from patients on virally suppressed HAART did not contain proviral DNA 
(100) suggesting partial recovery of mDC following anti-retroviral therapy may be due in part to 
decreased infection.  However, until the frequency of directly infected mDC in blood is 
determined, the pathogenic relevance of infection in DC loss remains speculative.    
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Similar to mDC, circulating pDC also express the HIV receptor CD4 and coreceptors CCR5 and 
CXCR4, and are susceptible to HIV infection in vitro (95-99) and infected in vivo in both 
humans (40) and macaques (54).  We identified approximately 4% of pDC were infected with 
SIV at the peak of plasma viremia in lymph nodes, implicating direct infection plays a minor role 
in pDC loss early after infection.  Preliminary evidence indicates that less than 1% of lymph 
node pDC are infected with SIV in animals with AIDS (data not shown) and macaque pDC are 
infected during the acute rather than the chronic phase of infection, when pDC numbers remain 
depleted (54).  Therefore, the continued role of direct infection in pDC loss as infection 
progresses remains to be determined. 
6.7 APOPTOSIS AND NECROSIS OF DC 
We showed that increased apoptosis or necrosis plays a role in the loss of both mDC and pDC in 
lymphoid tissues during acute SIV infection and animals with simian AIDS.   In peripheral 
lymph nodes and spleen, DC were more prone to spontaneous cell death in animals with AIDS.  
It is possible that apoptosis of DC in HIV and SIV infection is mediated by the binding of TNF 
family ligands to death receptors involving Fas/FasL binding or TRAIL/DR5 interactions, known 
to play a role in the apoptosis of T cells in HIV/SIV infection (115, 122-124, 164).  Indeed, both 
Fas- and TRAIL-mediated pathways have been implicated in mDC apoptosis during measles 
virus infection (127, 165).  However, an alternative mechanism may be responsible for pDC 
death.   
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During acute SIV infection, increased frequencies of late apoptotic/necrotic pDC were found 
associated with direct viral infection and increased expression of CD95 (Fas).  Although the 
direct effects of virus exposure on pDC death and survival are conflicting(50, 78, 97), pDC loss 
is likely due to both direct viral infection and indirect or ‘bystander’ killing mechanisms.  pDC 
exposure to, or endocytosis of HIV leads to increased pDC survival and activation(50, 79) not 
death, whereas exposure to virus-infected cells induces pDC death in a fusion-dependant 
manner(78).  The increased frequency of Fas-expressing pDC during acute SIV infection 
suggests pDC may be undergoing Fas-mediated death.  However, while Fas/FasL interactions 
play a role in CD4+ T cell loss in HIV and SIV infection(115, 183), evidence is lacking for this 
pathway in pDC death in HIV infection(78).  Ultimately, future studies will need to focus on 
elucidating the exact mechanisms leading to pDC death during pathogenic HIV/SIV infection. 
6.8 FUNCTIONAL TLR7 SIGNALING OF pDC DURING ACUTE SIV INFECTION 
Reduction in circulating type I IFN in HIV infected individuals is correlated with pDC loss and 
is generally thought to be due to impaired pDC function (46, 87, 91, 92, 169, 187), although this 
is rarely studied directly. Despite early and sustained pDC depletion, the frequency of pDC in 
lymph nodes simultaneously producing TNF-α and IFN-α following TLR7 stimulation was 
similar to uninfected macaques. Consistent with this finding, endocytosis of HIV-1 activates 
pDC via TLR7 (79) and pDC exposed to HIV-1 in vitro were functionally normal following 
TLR7 stimulation and stimulation-induced DC maturation did not increase HIV-1 replication 
(98).  It is possible that pDC function early in infection remains intact, and studies of HIV-
infected patients indicate that impaired production of IFN-α by pDC is most apparent in 
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individuals with advanced disease and stimulated via TLR9 (91, 93, 169).  Supportingly, direct 
interaction of HIV-1 gp120 interferes with TLR9 but not TLR7 activation of pDC (193), 
suggesting selective impairment of TLR9 signaling.  Whether IFN-α production by the limited 
number of surviving pDC in acute infection is sufficient to induce chronic CD4+ T cell activation 
in lymph nodes, as has recently been proposed (171, 188), remains to be determined. 
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7.0  PUBLIC HEALTH SIGNIFICANCE 
There are an estimated 37 million people living with HIV-1/AIDS worldwide and in 2007, there 
were 2.7 million new HIV infections and 2 million HIV-related deaths (1).  Moreover, HIV-
1/AIDS reduces the quality of life and impacts traditional family structures in areas with high 
prevalence of HIV, evidenced by the increasing number of AIDS orphans in Africa (1).  mDC 
and pDC play a critical role in bridging innate and adaptive immune responses and collaborate to 
induce potent anti-viral immunity.  Thus DC depletion during HIV infection likely contributes to 
the lack of adequate immune control.  Despite the benefits of anti-retroviral therapy in extending 
the survival of infected individuals, DC numbers and function remain below normal levels 
controls (38, 42-44, 46-49, 54, 84-87) .  The sustained DC alterations highlight the need to 
determine the mechanisms leading to DC loss and dysfunction during HIV-1 infection.  In this 
study, we found that DC loss during primary SIV infection was mainly driven by increased 
recruitment to lymph nodes and death, the latter being a common feature in systemic DC loss at 
the onset of AIDS.  Collectively, these findings suggest new therapeutic strategies aimed at 
reducing the dysregulation of DC trafficking and dysfunction is necessary for improved control 
of HIV-infection. 
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8.0  FUTURE DIRECTIONS 
8.1 FUNCTIONAL ROLE OF CD16 EXPRESSION BY mDC  
Evaluating the phenotypic complexity of rhesus macaque DC raises many questions regarding 
differences in DC biology between humans and rhesus macaques.  Firstly, CD16 is an Fc 
receptor that binds the Fc region of Abs, and cross-linking of Ab Fc receptors by Ab-opsonized 
Ag complexes initiates cellular immune responses, including phagocytosis, Ab-dependent cell-
mediated cytotoxicity (ADCC), respiratory burst, and release of cytokines and inflammatory 
mediators (194).  In rhesus macaques, sustained ADCC correlates with delayed onset of AIDS 
pathogenesis (195) and CD16 is critical for NK cell-targeted destruction of HIV-infected cells 
through ADCC (196).  However, CD16 expression also plays a role in viral persistence and 
transmission by follicular DC (197).    Therefore, the functional consequence of CD16 
expression by mDC in both humans and rhesus macaques and its role in the immunopathogenesis 
of HIV/SIV infection requires further exploration.   
 
The disparate expression of CD1c by species of macaques will need to be resolved as it may lead 
to alterations in the early dynamics of lentiviral infection.  Both cynomolgus macaque and 
human mDC express CD1c (25, 49) and in humans, HIV has been found to productively infect a 
subset of CD1c+ mDC in vitro (198).  However, during chronic SIV infection of cynomolgus 
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macaques, the absolute number of CD1c+ mDC were similar to pre-infection levels, leaving the 
effects of  infection on CD1c+ mDC in humans unclear. 
8.2 mDC DEPLETION IN BLOOD 
Both HIV and SIV infection lead to a significant reduction in the frequency of circulating mDC 
in blood.  However, the exact mechanism for this loss remains undefined.  A major unresolved 
factor in mDC loss is the frequency of direct infection in blood.  mDC are infected in vivo (40) 
but until the frequency of infection is known, the role of direct infection in mDC loss will remain 
speculative.  The major hypothesis proposed to account for DC loss has been recruitment to 
lymphoid tissues although support for this hypothesis is conflicting (52, 53).  mDC are mainly 
derived from bone marrow progenitor cells implicating a primary defect in hematopoiesis may 
lead to reduced mDC numbers.  Alternatively, monocytes may differentiate into DC under 
inflammatory conditions (20, 199), implicating a defect in mDC differentiation from monocytes 
during HIV/SIV infection may lead to mDC loss.  Therefore, future studies will need to 
determine whether mDC frequencies are reduced due to failures in hematopoiesis or monocyte 
differentiation.     
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8.3 INFLAMMATION-DRIVEN LOSS OF DC 
A characteristic of pathogenic SIV infection in nonhuman primates is a pronounced 
inflammatory response in lymphoid tissues (180, 200-202), including increased expression of 
CXCR3 ligands required for pDC recruitment (103, 104).  In addition, the CCR7 ligand CCL19 
is upregulated in lymphoid tissues during acute SIV infection, which may promote increased 
recruitment of activated DC to lymphoid tissues (179).  Treatment with anti-retroviral drugs 
decreases viral load in HIV/SIV infection associated with recovery of DC numbers in humans 
(38, 42, 44, 46-48).  In addition, anti-retroviral therapy is known to reduce immune activation in 
blood and lymph nodes in HIV infection (203-206) with recent evidence indicating restoration of 
pro-apoptotic factors such as Fas, TRAIL and caspase-3 to levels comparable to uninfected 
controls (207).  Moreover, non-pathogenic SIV infection of sooty mangabeys or African green 
monkeys, results in preservation of at least pDC numbers (89) as well as lack of inflammation 
and limited immune activation in lymphoid tissues (185, 208), which may be associated with 
differences in DC recruitment and death.  Therefore, exploring whether early anti-retroviral 
treatment reduces the inflammation driven recruitment of DC and death during SIV infection 
needs further exploration.   
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8.4 MECHANISM OF INCREASED DC APOPTOSIS 
It is clear from our findings that both mDC and pDC undergo increased levels of apoptosis or 
necrosis during SIV infection.  Apoptosis as a consequence of chronic immune activation is a 
well-described mechanism of T cell loss in HIV and SIV infection.  In nonpathogenic models of 
SIV infection, reduced inflammation leads to less T cell apoptosis.  It is clear from our findings 
that both mDC and pDC undergo increased levels of apoptosis or necrosis during SIV infection, 
indicating future experiments will need to address the exact mechanism leading to DC death.  
While the mechanism is likely to be complex, initial studies should focus on the effects of pDC 
exposure to virus-infected cells (78) and the role of TRAIL/DR5 or Fas/FasL signaling pathways 
in mDC death (209). 
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8.5 IMMUNOTHERAPEUTIC USE OF TLR7/8 AGONISTS 
TLR agonists are gaining increased interest as vaccine adjuvants (210).  In nonhuman primates, 
primary immunization with HIV Gag protein + a TLR7/8 agonist resulted in high frequencies of 
Th1 responses and increases in HIV Gag-specific CD8+ T cell responses after an adenoviral 
vector boost (211).  mDC infected in vitro with HIV respond to TLR7/8 ligation with full 
maturation and TNF-α production, similar to uninfected cells without increasing HIV-1 
replication (98).  In addition, direct interaction of HIV-1 gp120 interferes with TLR9 but not 
TLR7 activation of pDC (193) and TLR7 engagement of pDC leads to increased expression of a 
network of anti-apoptotic and pro-survival genes (212).  Thus, early therapeutic interventions 
targeting TLR7 and 8 may improve immunologic control of HIV by increasing survival of both 
mDC and pDC. 
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